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PRL-3, an oncogenic dual-specificity phosphatase, is over-expressed in 50% 
of AML and associated with poor survival. We found that stable expression of 
PRL-3 in the cytokine-dependent TF-1 AML cells confers cytokine-
independent growth, induces colony-forming ability in methylcellulose media 
and tumorigenesis in vivo. However, how PRL-3 mediates these functions in 
AML is unknown.  
 
To systematically characterize novel substrates of PRL-3 in leukemia, 
unbiased large-scale proteomics and phosphoproteomics analyses were 
performed between the parental TF-1 cells and their malignant PRL-3 
transfectant counterparts to discover critical differences in signaling networks. 
We obtained quantitative measurements on 803 proteins, where 331 were 
significantly up-regulated (>1.5-fold) and 67 were under-expressed (<0.6-
fold). More importantly, PRL-3 altered the phosphorylation status of 192 
proteins. We showed that Leo1, a component of RNA polymerase II-
associated factor (PAF) complex, is a novel and important mediator of PRL-3 
oncogenic activities in AML. We observed a two-level regulation of Leo1 by 
PRL-3, providing strong evidence that Leo1 is the pivot point of PRL-3 
oncogenesis. 
 
We described a novel mechanism where elevated PRL-3 protein increases 
JMJD2C histone demethylase occupancy on Leo1 promoter, thereby reducing 
the H3K9me3 repressive signals and promotes Leo1 expression. In addition, 
PRL-3 and Leo1 protein levels were positively associated in AML patient 
x 
 
samples (N=24; p-value <0.01). On the other hand, inhibition of Leo1 reverses 
PRL-3 oncogenic phenotypes in AML. Loss of Leo1 leads to destabilization of 
the PAF complex and downregulation of SOX2 and SOX4, potent oncogenes 
in myeloid transformation. Thus, PRL-3 modulates Leo1 expression levels to 
promote oncogenesis partially through the PAF complex. Our work also 
demonstrates a possible interface of how a phosphatase might be involved in 
transcriptional regulation. 
 
Independent of the PAF complex, Leo1 played an important role in the 
activation of β-catenin. We demonstrated that PRL-3 interacts with and 
dephosphorylates Leo1 in vitro and in vivo. Leo1 then forms a complex with 
β-catenin, and induces the nuclear retention and transcriptional activation of β-
catenin target genes, including c-myc and cyclin D1.  
 
Hence, our study revealed that the functional consequences of PRL-3 
overexpression in AML cells were pleiotropic and exploited the intracellular 
activation of two potent oncogenic pathways, SOX genes and β-catenin. In 
conclusion, this study unravels the network of downstream PRL-3 signaling 
pathways through identifying novel substrates, and the improved 
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1.1. Acute myeloid leukemia (AML) 
1.1.1. The hematopoietic system 
Hematopoiesis is the process of blood cells production by the expansion and 
differentiation of the hematopoietic precursor cells, which takes place in the 
bone marrow (BM) niche. The isolation of the hematopoietic stem cell (HSC), 
which has the ability to give rise to all the cells in the hematopoietic system, 
was one of the most important discovery, not only because it helped us to 
understand stem cell biology, it is also an important concept in HSC 
transplantation (Cumano A et al, 2007). HSCs are characterized by two 
important properties, namely self-renewal and multipotency. Multipotency is 
defined by the ability to give rise to different cell types from a single parent 
cell. Self-renewal through asymmetric division, allows the maintenance of the 
stem cell pool and as well form the more lineage-associated cells, i.e. common 
myeloid and lymphoid progenitors (Figure 1.1). This self-renewal property is 
assessed by in vivo long-term reconstitution experiments, where sequential 
transplantation of single hematopoietic cell in irradiated recipient animals 
could generate blood cells belonging to all lineages. HSCs can be further 
divided into long-term subset HSC (LT-HSC) and short-term subset HSC (ST-
HSC) (Zhong RK et al, 1996). LT-HSC are capable of indefinite self-renewal, 
while ST-HSC self-renew for a defined period of time. The LT-HSC is 
considered a true stem cell, with an estimated frequency of about 1 in 100,000 
murine BM cells (Harrison DE et al, 1993). When HSCs mature to more 





Adult HSCs are an extremely rare population of cells, and they undergo a 
decision to either self-renew or differentiate into the myeloid or lymphoid 
lineages. The common lymphoid progenitor give rise to T and B cells, while 
the common myeloid progenitor give rise to the granulocyte/macrophage 
progenitors (GMP) or megakaryocyte/erythroid progenitors (MEP). Using 
flow cytometry coupled with CD (cluster of differentiation) antibodies 
staining, it is possible to isolate and characterize discrete cell populations from 
the peripheral blood or bone marrow. Using several marker combinations such 
as Linneg, Thy1+, CD34+, CD38-, the human HSC populations can be enriched 
(Murray L et al, 1995). Several growth factors cocktail has been proposed to 
maintain HSCs in vitro, however, they are unsuccessful in preventing their 
differentiation or apoptosis in long-term cultures. This could be due to 
unknown growth factors or cell-surface molecules contributed by bone 
marrow stromal cells native to the microenvironment of the HSCs.  
 
Transcription factors play a major role in hematopoietic development. For 
example, SCL and RUNX1 (also known as AML1) factors play a pivotal role 
in fate commitment from haemangioblast to HSC, disruption of these factors 
would affect the formation of all blood lineages. On the other hand, 
manipulation of factors like PU.1, C/EBPα and GATA1 affects a limited 




Figure 1.1. The hematopoietic system. Hematopoietic stem cells (HSCs) 
give rise to two major progenitor cell lineages, myeloid (GMP) and lymphoid 
progenitors (CLP), which further give rise to the mature hematopoietic cell 
types (Orkin and Zon, Cell 132: 631, 2008). 
 
1.1.2. Biology of AML 
AML is a neoplastic disorder characterized by an accumulation of abnormal 
myeloid blasts, which are distinguished by the hyperproliferation of 
hematopoietic precursor cells with decreased apoptosis and impaired 
differentiation. In acute leukemia, the number of blast cells increased rapidly. 
These blast cells are relatively immature cells that were unable to carry out 
their normal functions, causing hematopoietic insufficiency. The clinical 
presentation of AML patients typically involves an increased rate of infections 
and fever, hemorrhage and fatigue. However, leukemic infiltration of other 
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organs, such as spleen, liver, lymph nodes, and central nervous system would 
result in other signs and symptoms (Bonnet et al, 1997; Lowenberg B et al, 
1999). The acute nature of this disease leads to rapid progression and requires 
immediate medical intervention. If left untreated, AML is fatal within weeks 
or months, with bone marrow failure as the common cause for death. AML is 
the most common acute leukemia in adults, and accounts for about 30% of all 
adult leukemia incidences. Incidence increases with age (Lowenberg B et al, 
1999).  
 
AML comprises a heterogeneous group of malignancies of hematopoietic 
progenitor cells with extensive molecular, cytogenetic and clinical 
heterogeneity, leading to varying outcomes with currently available treatments 
(Reiter A et al, 2004). A patient is diagnosed with AML when more than 20% 
of blast cells are present in the blood or bone marrow (Dohner H et al, 2010). 
The diagnosis relies on the identification of blast cells, characterized by a 
distinct nucleoli, round-to-irregular nuclei, and very little cytoplasm, in the 
preparations of peripheral blood and bone marrow sections stained with 
Wright–Giemsa (Lowenberg B et al, 1999).  
 
AML can be categorized based on the French-American-British (FAB) system 
into eight subtypes, M0 to M7 (Table 1), depending on the type and maturity 
of the cell that the leukemia developed from. This can be done by examining 
the blasts under microscope, or by using cytogenetics to examine presence of 
chromosomal abnormalities. More recently, surface markers, abnormal 
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enzyme activities and specific chromosomal translocations detected by 
molecular techniques like polymerase chain reaction (PCR) and fluorescent in 
situ hybridization (FISH) have improved classification schemes. The different 
subtypes have varying prognoses and responses to therapy. The FAB system 
was devised in 1976, which was later reviewed and revised in 1985 (Bennett J 
et al, 1976; Bennett JM et al, 1989). Another newer system to classify AML 
into subtypes is the World Health Organization (WHO) classification devised 
in 2001. Although the FAB system is more commonly used to classify AML 
subtypes, it does not consider many factors that affect prognosis. The WHO 
system aims to overcome this issue with the newer classification, and 
identifies signaling pathways that are amenable to molecular targeted therapies 
(Vardiman JW et al. 2009). 
Table 1: FAB Classification of AML and incidence of occurrence 
(Adapted from C. Chandra Kumar, 2011) 
 
1.1.3. Genetic abnormalities in AML 
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AML is characterized by a multitude of chromosomal abnormalities and gene 
mutations, and these aberrations are not mutually exclusive events in AML. 
Cytogenetic abnormalities occur in about 50-60% of newly diagnosed cases, 
and these balanced translocations are associated with gene rearrangements. 
Cytogenetics remains the most important prognostic factor for predicting 
remission and relapse rate, and overall survival (Martens JH et al, 2010). For 
example, the t(15;17) translocation resulting in the PML/RARα fusion in the 
case of acute promyelocytic leukemia gives distinct biological features and a 
favorable prognosis, and treatment involves the use of all-trans retinoic acid 
(Mandelli F et al. 1997). On the other hand, the prognosis for MLL-related 
rearrangements is poor. In these cases, the MLL protein can fuse to one of 
more than its 50 partner genes, and acts as a potent oncogene through DNA 
binding and sustained transactivation (Krivtsov AV et al. 2007). Table 2 
summarizes the most frequent chromosomal translocations and their 
corresponding fusion products in AML. Chromosomal abnormalities can 
occur as deletions, trisomies, balanced translocations and inversions involving 
part of or the whole chromosome. The resulting fusion product alters the 
expression of its downstream target genes, promoting leukemic transformation 











Table 2: Translocations and their fusion products (Adapted from C. 
Chandra Kumar, 2011) 
 
On the other hand, 40-50% of the AML cases have normal karyotype (Schlenk 
RF et al. 2008), requiring a more detailed molecular analysis of this group, 
which led to the identification of recurring gene mutations (Figure 1.2). These 
gene mutations can be broadly clustered into class I mutations conferring 
proliferation and/or survival advantage, and class II mutations that block 
differentiation with increased self-renewal capabilities. Class I mutations 
includes genes such as KIT, RAS and FLT3. Class II genes include CEBPα 
and NPM1.  
 
KIT is a member of type III receptor tyrosine kinase (RTKIII) family, and its 
ligand is stem cell factor (SCF). Ligand-independent activation of KIT caused 
by mutations leads to hyper-activation of oncogenic downstream signaling 
pathways (Lennartsson J et al. 2005). RAS encodes for guanine nucleotide-
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binding proteins that are involved in signal transduction through binding of 
membrane receptors. RAS proteins exist in an equilibrium of GTP-bound and 
GDP-bound forms, which represents the active and inactive state of the protein 
respectively. Gene mutations frequently abolish the GTPase activity, thus 
conferring constitutive activation of RAS and downstream effectors like RAF 
and MAPK/ERK (Mitin N et al. 2005). FLT3 (Fms-like tyrosine kinase 3) 
encodes for a receptor tyrosine kinase belonging to the RTKIII, which is 
expressed by immature hematopoietic cells and is crucial to the differentiation, 
proliferation and apoptosis of hematopoietic cells. In AML, the FLT3 gene 
possessed an internal tandem duplication (ITD) in the juxtamembrane domain 
(Nakao M et al. 1996), which causes ligand-independent dimerization and 
tyrosine auto-phosphorylation, rendering it constitutively active. The 
frequency of FLT3-ITD in patients is about 25–35% in adults, and is 
associated with poor prognosis and lower survival rates as compared to 
patients with wild-type FLT3.  
 
The CEBPA gene belongs to the CCAAT/enhancer-binding protein family, a 
transcription factor important during the early stages of differentiation. 
Through its DNA binding and protein-protein interactions, it inhibits 
proliferation and upregulates the expression of lineage-specific genes 
(Radomska HS et al. 1998). Experiments have confirmed that loss of CEBPA 
function facilitates leukemogenesis by blocking granulocyte differentiation 
(Pabst T et al. 2001). NPM1 is a multifunctional phosphoprotein that is able to 
shuttle between the cytoplasm and nucleus, with a predominant localization in 
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the nucleus. Almost all mutations cause frameshifts in the C-terminal region of 
the NPM1 protein, resulting in the loss of the residues which determine 
nucleolar localization. The resultant aberrant cytoplasmic localization and 
acquisition of new binding partners predisposes to leukemogenesis (Verhaak 
RG et al. 2005).  
 
Other than NPM1 and FLT3, recent targeted sequencing efforts on 
cytogenetically normal AML genome have led to the discovery of recurring 
mutations on newly implicated genes, including TET2 (Delhommeau F et al. 
2009), while massively parallel sequencing has led to the discovery of 
mutations in DNMT3A (Yamashita Y et al. 2010)  and IDH1/2 (Mardis ER et 
al. 2009). These novel mutations may provide prognostic value, especially for 
the intermediate-risk AML group (Patel JP et al. 2012, Shen Y et al. 2011, 
Mrózek K et al. 2012). 
 
 
Figure 1.2. Occurrence of molecular aberrations in adult AML. (Adapted 




1.1.4. Management of AML 
1.1.4.1. Standard of care 
AML has an incidence rate of 3.7 per 100,000 people per year, and the median 
age at diagnosis is 67 years old in the USA. Despite the relatively low 
incidence, the five-year survival rate is only 24.2% 
(http://seer.cancer.gov/statfacts/html/amyl.html). In Singapore, leukemia is a 




Despite significant progress in understanding the pathogenesis of AML, the 
disease is curable only in 30% of the patients (Falini B et al. 2005), and 
remains a therapeutic challenge in children and elderly patients as treatment 
still revolves around combinational chemotherapy. Given the toxicity 
associated with chemotherapy, this type of treatment is often not tolerated in 
elderly patients, resulting in poor overall and event-free survival (Figure 1.3). 
Problems associated with the usage of chemotherapy to manage AML include 
frequent relapse rate, poor response, acquired resistance and myelo-
suppression. The primary objective for treatment is to achieve and maintain 
complete remission. Complete remission is defined as a bone marrow with less 
than 5% blast cells. The recurrence rate of AML sharply declines after 3 years 




The treatment regimen for AML consists of two stages: 1) remission induction 
phase and 2) post-remission therapy. It involves chemotherapeutic agents such 
as cytarabine (Ara-C) in combination with an anthracycline (daunorubicin or 
idarubicin) in the induction phase, followed by multiple cycles of intensive 
post-remission therapy with elevated-dosage of Ara-C (Mayer RJ et al. 1994). 
In the induction phase, the goal is to achieve a marked reduction in the 
leukemic blasts in the blood and bone marrow such that normal hematopoiesis 
can occur. In general, remission can be achieved in 65% to 85% of younger 
patients, but declined to less than 50% in patients older than 60 years old (Ho 
C et al. 2011). For patients who did not achieve complete remission following 
induction phase, another cycle of the same induction therapy can be used. 
Alternatively, if the response to the induction therapy has been poor, an 
alternative induction regimen based on fludarabine will be used.  
 
The post-remission phase aims to kill residual leukemic cells to prevent 
disease relapse. During consolidation treatment, additional chemotherapy was 
given at higher doses of the same drugs given during induction phase. For 
patients who received induction therapy alone, the median disease-free 
survival is about 4 to 8 months, whereas those who received consolidation 






Figure 1.3. Kaplan-Meier Survival analysis on adults and elderly with 




1.1.4.2. Stratification of post-remission therapies according 
to genetic risks 
The cytogenetic and molecular profiles of AML patients can be used to stratify 
patients into various risk groups, which affects the decision of post-remission 
treatment. Patients can be broadly classified into favorable-risk AML, 
intermediate-risk AML and adverse-risk AML (Dohner H et al. 2010).  
 
For favorable-risk AML, choice of treatment is multiple cycles of high-dose 
cytarabine. This treatment is suitable for patients with core binding factor 
AML (CBF-AML), AML with mutated NPM1 (without FLT3 activation) or 
mutated CEBPA, which predicts a more favorable prognosis (Schlenk RF et 
al. 2008). Autologous or allogenic HSC transplantation is generally not 
recommended for this group of patients as there is no additional benefit. In 
patients with normal karyotype, repetitive cycles of high-dose cytarabine is 
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insufficient, with unsatisfactory outcomes and high relapse rate. Therefore, 
allogenic HSC transplantation is an attractive option for these patients 
belonging to the intermediate-risk subset (Yanada M et al. 2005). For patients 
with high-risk cytogenetic profiles, they are considered the adverse-risk group 
and HSC transplantation is highly recommended (Slovak ML et al. 2000). 
 
1.1.5. Leukemic stem cells (LSCs) 
It is now well known that cancer arises from a small number of leukemic stem 
cells (LSCs) that are capable of initiating and maintaining the disease. Several 
studies have demonstrated that only a small population of leukemic cells are 
capable of long-term clonogenic growth in vitro and in vivo. LSCs isolated 
from human AML were the only cells capable of transferring leukemia into 
NOD/SCID mice, and they represent only about 0.2-1% of the total leukemic 
cell population in the patient (Bonnet et al. 1997). The study of chronic 
myeloid leukemia (CML) also served as an important model of a specific 
chromosomal translocation as the causative agent, and the clonal nature of this 
disease. It was discovered that essentially every blast cell in a CML patient 
carry the BCR-ABL fusion protein, which makes targeted therapy with 
Imatinib (Gleevec) a successful therapy in this particular type of leukemia. A 
phenomenon, called “oncogene addiction”, was also coined to describe the 
dependence of these blast cells towards a certain oncogene acquisition, such 
that a simple “shut-down” of the oncogene activity is sufficient to cause 




There are two main hypotheses regarding the origin of a LSC. It has been 
proposed that LSCs developed from HSCs through the acquisition of 
transforming events that took place in HSCs.  Since HSCs persist throughout 
life, they have a greater likelihood of developing mutations. Furthermore, in 
many biological aspects, a LSC resembles a HSC. This concept appears to be 
valid in most subtypes of human AML. In these group of leukemias, only the 
CD34+CD38- population is capable of transplanting AML in NOD/SCID mice, 
while the CD34+CD38+ population of leukemic blast cells was unable to do so  
(Bonnet et al. 1997). In the case of t(8,21) translocation that fuses AML1 and 
ETO genes, the translocation can be found in normal HSCs and additional 
mutations in a subset of these HSCs drive leukemic development (Miyamoto 
T et al. 2000). 
 
Alternatively, LSCs may also arise from the committed progenitors through 
gene mutations or over-expression of oncogenes that enhance their self-
renewal capabilities. For instance, in acute promyelocytic leukemia (APML) 
(FAB M3) it was found that the PML/RARα fusion product, was present in the 
CD34-CD38+ population, but not in the CD34+CD38- population that is 
enriched for HSCs (Turhan AG et al. 2005). Thus, despite the controversies 
revolving around the origin of LSCs, it appears that both hypotheses were 
valid, as the origin of LSCs differs in different subtype of leukemia (Passegué 
E et al. 2003).  
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1.2. Post-translational modifications (PTM) 
1.2.1. How PTM regulates protein functions 
Post-translational modifications (PTMs) are covalent modifications on 
eukaryote proteins that increases the functional diversity and complexity of the 
proteome. These modifications include phosphorylation, ubiquitination, 
acetylation, methylation and proteolysis (Mann M et al. 2003), just to name a 
few (Figure 1.4). Enzymes involved in PTMs reversibly or irreversibly alter 
the structure and properties of their target proteins through biochemical 
reactions. Altogether, the PTMs are involved in a myriad of cellular events, 
including signal transduction, protein-protein interaction, activity, cellular 
localization and cell communication (Deribe YL et al. 2010). Given the pivotal 
involvement of PTMs in normal cell physiology, defects in PTMs have been 
the casual link to numerous developmental disorders and human diseases. 
 
To realize the full extent and functional importance of PTMs, a sensitive and 
analytical method for characterizing protein has been developed - Mass 
Spectrometry. Similar to the development of PCR and automated sequencer 
for DNA analysis, mass spectrometry serves the same purpose for proteins. 
Together with labeling and purification strategies, mass spectrometry can even 
characterize functional ‘subproteomes’, such as phosphorylated proteins and 









Protein phosphorylation in a cell is a dynamic and tightly-controlled process 
through the equilibrium actions of protein kinases and protein phosphatases. In 
eukaryotic cells, phosphorylation occurs predominantly on three hydroxyl-
containing amino acids, namely threonine, tyrosine and serine. More than 500 
putative protein kinases (Manning G et al. 2002) are encoded in the human 
genome, and can be classified into tyrosine kinases (PTK) or serine/threonine 
kinases (PSK). On the other hand, there are only about 100 putative 
phosphatases (Alonso A et al. 2004). Knowledge of the molecular actions of 
protein kinases have greatly outpaced that of phosphatases, attributing to the 
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fact that protein kinases were discovered almost a decade ahead of protein 
phosphatases. 
Protein kinases recognize specific motifs, which are surrounding sequences of 
phospho-sites, and add a phosphate-group (Kobe B et al. 2005), whereas 
phosphatase tend to be more promiscuous in their recognition of substrates. 
Protein phosphatases are defined by the active sequence C(X5)R, also known 
as the PTP signature motif. The invariant and highly conserved cysteine 
residue is essential for catalytic activity, and the arginine stabilizes the 
cysteine-phosphate intermediate. The ability of protein phosphatases to 
differentiate between substrates is dependent on the inherent specificity within 
the catalytic domain and the subcellular localization of the protein 
phosphatases as determined by its N- and C-terminal segments of the protein. 
In addition, there are unique issues and challenges in identifying the 
physiological substrates of protein phosphatases. 
 
A large-scale proteomic analysis of 6600 phosphorylation sites on 2244 
human proteins revealed that phosphoserine (pS), phosphothreonine (pT) and 
phosphotyrosine (pY) represent 86.4%, 11.8%, and 1.8% of phosphorylation 
sites in a cell (Olsen JV et al. 2006). The phospho-group (+80Da) can be 
stable on phosphotyrosine sites or relatively labile in the case of 
phosphotheronine and phosphoserine sites.  
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1.3. Phosphatase of regenerating liver-3 (PRL-3) 
1.3.1. PRL-3 and its functional domains 
Phosphatase of regenerating liver-3 (PRL-3), encoded by the PTP4A3 gene, is 
a small dual-specificity phosphatase characterized by the conserved C(X5)R 
catalytic domain, and a unique C-terminal prenylation domain essential for its 
proper subcellular localization (Zeng Q et al. 2000; Al-Aidaroos et al. 2010) 
(Figure 1.5). PRL-3 belongs to the PRL subgroup of protein tyrosine 
phosphatase (PTPs), which consists of PRL-1, PRL-2 and PRL-3, with an 
amino-acid similarity of 76-87% between the members. PRLs are highly 
conserved across different species (Al-Aidaroos et al. 2010), suggesting the 
importance of the PRLs in development. Being a dual-specificity phosphatase, 
PRL-3 exhibits activity towards a myriad of substrates that contains phosphor-
tyrosine, -serine and -threonine residues (Patterson KI et al. 2005; MacParland 
V et al. 2011). Although phosphatases are generally thought to antagonize 
signaling cascades initiated by kinases and thus inhibit cellular processes, 














Figure 1.5. Functional domains in PRL-3 and amino acid sequence 
alignment of PRL-3 in different species. There are a few evolutionary 
conserved domains of PRL. The PTP domain is responsible for the catalytic 
activity of PRL-3, while the C-terminal prenylation motif tethers the protein to 
membrane structures (Al-Aidaroos et al. 2010). 
 
1.3.2. Oncogenesis of PRL-3 in human solid cancers 
PRL-3 was first linked to cancer when it was consistently found at elevated 
levels in colorectal cancer (CRC) metastases, but at much lower levels in 
matched early-staged tumor and normal colorectal epithelium (Saha S et. al. 
2001) (Figure 1.6). Since then, elevated expression of PRL-3 has been 
implicated in the progression and metastasis of an array of cancer types, 
including gastric, ovarian, cervical, lung, liver and breast. Importantly, PRL-3 
protein was found overexpressed in an average of 22.3% of 1008 human 
carcinoma samples that were examined using immunohistochemistry (Bardelli 





Figure 1.6. Gene expression of PRL-3 in various stages of colorectal 
cancer. PRL-3 expression is only present in the metastatic stage of colorectal 
cancer but absent from the normal epithelium and primary colorectal cancer, 





Figure 1.7. PRL-3 expression in human cancers. PRL-3 antibody was used 
to probe the expression and localization of PRL-3 in multiple human patient 
samples, and signals were mainly detected on the membranes (Wang H et al. 
2010). 
 
In cancer, PRL-3 promotes cellular processes such as cell motility, invasion, 
cell growth and survival through various mechanisms (Kato H et al. 2004; 
Polato F et al. 2005; Radke I et al. 2006; Al-Aidaroos et al. 2010; Chu ZH et 
al. 2011; Jiang Y et al. 2011). PRL-3 is known as a metastasis-associated 
phosphatase, facilitating processes such as cell motility through association 
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with cytoskeletal remodeling proteins like Rho and Rac GTPases, and 
regulating focal adhesion proteins such as integrins, Src and paxillin. In 
addition, other membrane proteins like Ezrin (Forte E et al. 2008) and Keratin 
8 (Mizuuchi E et al. 2009) were identified as direct substrates of PRL-3 
phosphatase. To support metastasis, PRL-3 also promotes cell invasion by 
increasing the activities of matrix metalloproteinases (MMPs) to degrade the 
extracellular membrane, facilitating movement of tumor cells. PRL-3 also 
downregulates epithelial markers E-cadherin and upregulates mesenchymal 
markers, which in concert, contributes to epithelial-mesenchymal transition. 
 
There are several studies that demonstrated the metastatic properties of PRL-3. 
Overexpression of PRL-3 in chinese hamster ovary (CHO) cells increased the 
migration and invasive properties of the cells (Figure 1.8), while knockdown 
of PRL-3 in metastatic B16-BL6 melanoma cells significantly reduced the 
migration and invasive properties of these cells (Figure 1.9). Treatment of 
mice containing PRL-3 tumors using PRL-3 siRNA also prolonged the 
lifespan of these mice as compared to treatment with control siRNA (Figure 







Figure 1.8. Overexpression of PRL-3 in CHO cells. After PRL-3 
overexpression, there is an increased migration and invasive ability of these 
cells (Zeng Q et al. 2003). 
 
 
Figure 1.9. Knockdown of PRL-3 in highly metastatic B16-BL6 melanoma 
cells. After PRL-3 knockdown using siRNA, there is a reduction in migration 
and invasive ability, and higher survival rate of PRL-3 tumor-containing mice 
(Qian F et al. 2007). 
 
Ectopic expression of PRL-3 has also been found to promote the cellular 
proliferation and survival of various cell lines (Matter WF et al 2001; Werner 
SR et al 2003; Ming J et al 2009). PRL-3 enhances cell proliferation and 
survival through various mechanisms, such as promoting PI3K-Akt signaling 
pathway partially through abrogation of the negative regulator PTEN, or 
enhanced degradation of p53 mediated by Mdm2 phosphorylation. The ability 
of PRL-3 to promote survival can be seen in the resistance towards p53-




The oncogenic properties of PRL-3 are dependent on the phosphatase activity 
conferred by the C(X5)R and WPD motifs, which are involved in the catalysis 
of the phosphate group. Mutations of the essential active site cysteine 104 to 
serine (C104S), or aspartate 72 to alanine (D72A) ablate the phosphatase 
activity and sufficiently reverses most of the oncogenic phenotypes. For 
example, while the expression of wild-type PRL-3 enhances cell migration 
and proliferation in HEK293 cells, introduction of the C104S mutant 
displayed a similar phenotype as the vector control (Liang F et al. 2007).  
 
1.3.3. Regulation of PRL-3 
PRL-3 has been reported to be regulated at multiple levels in different cancer 
types. Increased PRL-3 gene copy number and amplification can be found in 
colorectal cancer metastasis and several myeloma cell lines (Saha S et al. 
2001; Buffart TE et al. 2005; Fagerli UM et al. 2008). However, in some 
cases, the gene copy number does not correlate to the mRNA levels (Saha S et 
al. 2001; Polato F et al. 2005), suggesting regulation at other levels. 
 
Interestingly, PRL-3 is identified as a p53-inducible gene in a screen for genes 
involved in p53 response to DNA damage in primary cells (Basak S et al. 
2008). It was reported that p53 directly bind to the promoter region of PRL-3 
gene to activate transcription. Since p53 is a potent tumor suppressor that 
causes cell-cycle arrest or apoptosis in cancer cells, PRL-3 as a downstream 
target would suggest a similar tumor suppressor role, contrary to the pro-
oncogenic reports of PRL-3. However, the authors addressed this issue when 
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they found that PRL-3 mediated cell-cycle arrest is highly dependent on 
genetic background of the cell.  
 
Stat3 has also been predicted to regulate PRL-3 promoter, and is proven in 
myeloma cells whereby stimulation with cytokine interleukin-6 (IL-6) 
promotes Stat3 activity and upregulation of PRL-3 (Figerli UM et al. 2008).  
 
It has been observed that the protein levels of PRL-3 do not correlate to the 
transcript levels in cancer cell lines, suggesting that PRL-3 is regulated at the 
translational level. It was found that the 5’-UTR of PRL-3 mRNA harbours 
cis-regulatory elements that can negatively regulate PRL-3 translation. This 
process is mediated by PCBP1, which binds specifically to the GC-rich motif 
in the 5’-UTR to inhibit PRL-3 expression. Given the inverse correlation 
between PRL-3 and PCBP1, overexpression of PCBP1 is sufficient to inhibit 
tumourigenesis of HCT-116 CRC cells injected into nude mice (Wang H et al. 
2010).  
 
FKBP38 is a PRL-3 binding protein identified through the yeast-two hybrid 
system in a screen for novel PRL-interacting proteins. FKBP38 was found to 
regulate endogenous PRL-3 turn-over rate through direct binding mediated by 
the N-terminal region of FKBP38, and promoted degradation of PRL-3 protein 
via protein-proteasome pathway (Choi MS et al. 2011). On the other hand, 
TGFβ signaling is also found to negatively regulate PRL-3 in CRC. TGFβ 
suppressed PRL-3 expression at the transcriptional level through inhibiting the 
promoter activity, and this process is SMAD2- and SMAD3-dependent. 
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SMAD2 and SMAD3 specifically bind to recognition sequences on PRL-3 
promoter as confirmed by electrophoresis mobility shift assays (EMSA) and 
ChIP assays (Jiang Y et al. 2011). 
 
In an interesting study, PRL-3 was also found to be targeted by microRNAs in 
gastric cells. The authors first found that PRL-3 is abnormally overexpressed 
in gastric carcinoma as compared to normal gastric samples. On the other 
hand, they observed an inverse correlation of the levels of miR-495 and miR-
551a with PRL-3, and found that they were significantly downregulated in 
gastric carcinoma. This suggested that miR-495 and miR-551a could suppress 
PRL-3 expression in normal gastric cells through binding the 3’UTR thereby 
inhibiting translation or causing mRNA instability. Furthermore, 
overexpression of miR-495 and miR-551a inhibited migration and invasion of 
gastric cancer cells. Hence, the results imply that miR-495 and miR-551a 
work as tumor suppressors in gastric carcinoma through inhibition of PRL-3 
(Li Z et al. 2012). 
 
Finally, PRLs are also regulated by oxidation at its C-terminal prenylation 
residues. In PRL proteins, oxidation at the nucleophilic C104 residue inhibits 
the phosphatase activity by promoting disulfide bond formation with another 
cysteine residue at C49. The disulfide bond that is formed is reversible, and 
reduction can be achieved through the presence of reducing agents. Thus, for 
maximum enzymatic function of PRL, reduction at the active site C104 must 
precede. Under normal conditions, the C104 residue is extremely reactive at 
physiological pH, however, the high reactivity also renders the C104 highly 
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susceptible to oxidation. PRLs also contain a C-terminal prenylation CAAX 
motif, that influences its subcellular localization. The prenylation motif allows 
farnesylation at the cysteine residue, followed by proteolytic cleavage of the 
AAX peptide and methylation. Farnesylated PRLs are directed to the nucleus, 
while lack of prenylation allows PRLs to tether to cell membranes. As the 
nucleus is also the most reducing organelle in the cell, it will be the most 
appropriate environment for optimal phosphatse activity of PRLs (Skinner AL 
et al. 2009). 
 
1.3.4. PRL-3 as therapeutic targets in cancer 
Considering the high amino-acid similarity between members of the PRL 
family, they have distinct patterns of expression. PRL-1 and PRL-2 are more 
ubiquitously expressed, whereas PRL-3 demonstrated a highly restricted basal 
pattern of expression in adult tissues (Bessette DC et al. 2008, Al-Aidaroos et 
al. 2010). Since the expression of PRL-3 is low in normal tissues, and elevated 
in cancerous cells, PRL-3 is deemed as an attractive therapeutic target which 
spares normal tissues. In fact, a recent discovery introduced the potential of 
targeting intracellular PRL-3 protein for anti-cancer therapy. By using PRL-3 
specific antibodies, Guo K et al. demonstrated the effective blockade of tumor 
progression induced by the PRL3-expressing cells that were injected into 




Figure 1.10. Targeting PRL-3 with immunotherapy. Intracellular PRL-3 
can be targeted using antibodies, mediating an anti-cancer activity (Guo K et 
al. 2011). 
 
1.3.5. PRL-3 as a novel oncogene in AML 
While PRL-3 has been extensively studied in solid tumors (Figure 1.11), its 
role in hematological malignancies is under-explored. In recent years, 
accumulating evidence suggests that PRL-3 is also a novel therapeutic target 
and biomarker in hematological malignancies (Fagerli UM et al. 2008; 
Beekman R et al. 2011; Zhou J et al. 2011). PRL-3 gene expression was found 
to be highly expressed in plasma cells from multiple myeloma (MM) patients 
and cell lines as compared to normal plasma cells, and PRL-3 protein was 
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found exclusively in the MM bone marrow samples. The high levels of PRL-3 
contributed to the enhanced migratory ability of MM cells in the dissemination 
of the disease (Fagerli UM et al. 2008).  
 
Our laboratory was the first to report that elevated PRL-3 protein expression 
occurs in about 47% of human AML cases while absent from normal myeloid 
cells in bone marrow (Zhou J et al. 2011) (Figure 1.12). In addition, a large-
scale gene expression profiling study of 454 primary AML samples 
demonstrates that high PRL-3 gene expression is an independent negative 
prognostic factor in AML, both for overall survival and event-free survival 
(Beekman R et al. 2011) (Figure 1.13). Differential gene expression profiling 
between BCR-ABL-positive and -negative in acute lymphoblastic leukemia 
(ALL) samples also identified PRL-3 as an upregulated gene related to BCR-
ABL status. These reports collectively suggest that PRL-3 may be of 






Figure 1.11. Timeline of publications relating to PRL-3 from 1994 to 
2010. First article reporting the role of PRL-3 in multiple myeloma in 2008 
(Al-Aidaroos et al. 2010).  
 
 
Figure 1.12. Immunohistochemistry (IHC) of PRL-3 in AML versus 
normal bone marrow sample.  PRL-3 staining can be observed on the 
cytoplasm of myeloid cells, but absent from the bone marrow of normal 





Figure 1.13. Survival analysis of AML cases with differential PRL-3 gene 
expression. A cohort of 454 AML cases were analyzed for overall and event-





1.4. The substrate perspective of PRL-3 
1.4.1. Reported substrates of PRL-3 
Despite the multiple articles on elucidating PRL-3 functions and involvement 
in various oncogenic pathways, further PRL-3 studies have been hampered by 
the insufficient knowledge of the direct physiological and pathological 
substrates of PRL-3. However, progress in this area is limited and challenging. 
This problem is common to all phosphatases, because unlike their kinase 
counterparts, phosphatases tend to be more promiscuous and the nature of the 
phosphatase-substrate interaction is transient. Despite these challenges, there 
are a few reports that aim to identify the targets that are differentially 
regulated by PRL-3. These reports will be discussed here as they set the 
precedence and represent the literature that were closely related to our work.  
 
One of the earlier strategy used to identify PRL-3 interacting proteins was the 
yeast two-hybrid system. Using this method, proteins such as integrin α1 
(Peng L et al. 2006) and CDH22 (Liu Y et al. 2009) were identified. However, 
an interaction does not necessary mean that it is a substrate of PRL-3. In the 
case of integrin α1, the authors found that the amount of tyrosine 
phosphorylation on integrin β1, which forms a heterodimer with integrin α1, 
was decreased in PRL-3 overexpressing cells. Through dephosphorylation of 
integrins, it increases the binding ability of integrin β1 to talin, a key effector 
in integrin signal transduction and promotes cell migration and metastasis. 
CDH22, a member of the cadherin family, was also identified as a PRL-3 
interacting protein through yeast two-hybrid and involved in promoting 
epithelial mesenchymal transition (EMT). 
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Proteomic analysis is another method to identify PRL-3 targets. Basically, this 
encompasses the large-scale identification of differentially-regulated proteins 
between two or more cell populations. Stathmin and translationally controlled 
tumor protein (TCTP) were identified in this manner. Stathmin plays a key 
role in regulation of the microtubule cytoskeleton, and thus is important in cell 
proliferation and migration. Through the use of two transient PRL-3 
knockdown cell models and a stable PRL-3 knockdown cell line of CRC 
origin, stathmin was identified to be downregulated with PRL-3 knockdown 
(Zheng P et al. 2010). The authors further found a positive interaction of 
stathmin and PRL-3 through co-immunoprecipitation and co-localization 
experiments. The activity of stathmin is known to be regulated by 
phosphorylation/dephosphorylation on serine residues. Phosphorylated 
stathmin has to be reactivated by dephosphorylation in order for cells to exit 
mitosis and enter a new interphase. However, the authors did not perform 
experiments to determine the phosphorylation status of stathmin. Similarly, 
TCTP was also identified when comparing control and PRL3-overexpressing 
CRC cells, and found to be implicated in proliferation, migration and invasion 
(Chu ZH et al. 2011).  
 
More recent studies aim to determine the direct cellular substrate of PRL-3. 
One report identified keratin 8 as a physiological interacting protein of PRL-3 
and alteration of the S73 and S431 phosphorylation sites in colorectal cancers 
(Mizuuchi E et al. 2009). This report is a comparative study involving CRC 
cells transfected with either wild-type or C104S mutant PRL-3 in SW480 
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cells. 48 hours after transfection, whole protein extract was subjected to 2D-
PAGE and phosphorylated proteins were visualized by Pro-Q Diamond 
staining. The phospho-protein spots that were increased in C104S transfectants 
as compared to wild-type PRL-3 were subjected to MALDI-TOF and MS 
analysis, which led to the identifcation of keratin 8. Inhibition of PRL-3 
increased phosphorylation of S73 and S431 of keratin 8, while overexpression 
of PRL-3 resulted in dephosphorylation of these phospho-sites. Furthermore, 
there was a positive interaction between PRL-3 and keratin 8, and 
colocalization was observed at cellular lamellipodias and ruffles. This 
suggested that PRL-3 regulates keratin 8 to promote cancer cell migration in 
colorectal cells.  
 
Ezrin was also identified in a similar manner by comparing phospho-patterns 
of 1D-PAGE between colorectal cells with transient expression of wild-type 
PRL-3, D72A or C104S/D72A. PRL-3 was found to alter Ezrin-Thr567 
predominantly (Forte E et al. 2008). However, 1D or 2D gel electrophoresis 
has several limitations, such as low resolution, bias against membrane 
proteins, visualization of proteins with high abundances and rarely 
reproducible. As a result of these limitations, 2D gel electrophoresis haven 
been superseded by MS-based proteomics coupled with metabolic (SILAC) or 
chemical labeling. 
 
1.4.2. Methods to identify bona fide PRL-3 substrates 
There are three proposed criteria to assign a phosphorylated protein as a 
phosphatase substrate (Tiganis T et al. 2007). Firstly, direct interaction of the 
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substrate with a substrate-trapping mutant of the phosphatase. The concept of 
substrate-trapping mutants center around the concept that cysteine to serine 
(C-S) or aspartate to alanine (D-A) mutations allow the stable interaction of 
the phosphatase with their cognate substrates, trapping the substrates in the 
catalytic pocket. These mutations retain the ability to bind to substrates, 
however, the nucleophilic attack on the substrates could not occur. In certain 
cases, the use of double mutations, meaning both C to S and D to A on the 
same phosphatase, may further improve the substrate-trapping efficiency. The 
residues that were chosen for mutations should not alter the conformation of 
the phosphatase. In this strategy, the substrate-trapping mutant will be 
expressed in the relevant cell line and isolated using a biochemical approach 
like immunoprecipitation. The substrate should form a stable interaction with 
its endogenous substrate, whereas the wild-type phosphatase do not interact, or 
interact to a lesser extent. This approach has been rigorously developed 
through characterization of improved substrate-trapping mutants with a higher 
affinity for its less abundant substrates. For example, phosphatases like PTP1B 
and SHP2 has been very well-studied in this aspect (Flint AJ et al. 1997; Xie L 
et al. 2002; Lee H et al. 2006). 
 
Secondly, the phosphorylation level of the putative substrate must be 
modulated by the phosphatase. Overexpression of the wild-type phosphatase is 
performed and should correlate to a decrease in phosphorylation levels of the 
substrate. A good control will be to include the overexpression of substrate-
trapping mutant, which traps the substrate and prevent its dephosphorylation 
by endogenous phosphatases, resulting in a hyper-phosphorylation of the 
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substrate. To exclude the possibility of artifacts arising from overexpression 
systems, for example, a mislocalization of the overexpressed phosphatase, 
knockdown of the phosphatase using RNAi approach should also complement 
such studies.  
 
Substrates usually have multiple phosphosites on serine, threonine and 
tyrosine residues. If the phosphatase dephosphorylates few sites, it may be 
difficult to detect phosphorylation changes when looking at net 
phosphorylation levels. In this instance, specific phospho-antibodies targeting 
the discrete site and knowledge of the discrete site is necessary. However, 
identification of specific phospho-sites is not an absolute requirement for 
assigning substrates. 
 
Thirdly, demonstrating the in vitro dephosphorylation of the substrate by the 
phosphatase. In this approach, purified wild-type phosphatase is mixed with 
the substrate, and monitored for dephosphorylation using either anti-phospho 
antibodies or release of phosphate in a colorimetric or radioactive assay. 
Although this approach is fairly straight-forward, it may be an over-
representation of the ability of the phosphatase to dephosphorylate its 
substrates. For example, there are additional regulatory mechanisms of the 
phosphatase in the cell that are absent in vitro that dictates its activity. 
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1.5. SILAC-based Mass Spectrometry (MS) 
1.5.1. Differential labeling using SILAC  
Stable isotope labeling by amino acids in cell culture (SILAC) is a metabolic, 
non-radioactive cell-labeling method that was originally described ten years 
ago (Ong SE et al. 2002), and shown to be a superior method that allows 
simultaneous comparison of protein mixtures from more than one cell 
population. Since mammalian cell lines require the supplementation of 
essential amino acids in the culture media to grow, SILAC media supplements 
isotopically-labeled forms of essential amino acids instead of normal amino 
acids e.g. 13C6-lysine, which will be incorporated into the proteome of cells 
and introduce a mass shift of six daltons when detected with MS (Figure 1.14). 
And since the isotope label is incorporated into the proteome, the cell 
populations that are differentially labeled can be mixed directly after cell 
harvesting, reducing any sample handling errors. Importantly, use of these 
amino acids does not alter cell phenotypes like cell growth and morphology. 
Since this method relies on a mass shift in the peptides and proteins to 
differentiate between the cell populations, it is important to ensure complete 
incorporation through at least 5-6 doublings in SILAC media to eliminate 
differences in labeling efficiency. Trypsin is the protease commonly used in 
SILAC experiments due to its specificity in recognition and cleavage at lysine 
and arginine residues. Together with the use of isotope-labeled lysine or 
arginine amino acids in SILAC, almost all peptides that were generated 
contains a label thus making it quantifiable (Aebersold R et al. 2003; SE Ong 





Figure 1.14. SILAC metabolic labeling of control cells with “Light” 
medium and cells of interest with “Heavy” medium (Ong SE et al. 2006). 
 
Mass spectrometry is not an inherently quantitative method (Mann M et al. 
2006). However, peak ratios for isotopic analogs used in a SILAC experiment 
are quantitative as there are no chemical differences between the species, and 
peptides are analyzed in the same experiment. Due to the mass shift, each 
peptide would appear as a doublet (if analyzing two cell populations), and the 
signal intensity/peak ratios represent the difference in the abundances of the 
protein. On the other hand, an almost equal intensity would suggest that the 
protein is expressed at similar levels between the two cell populations. For 
example, a housekeeping protein like β-actin or GAPDH would show a ratio 
of one. 
 
Thus, SILAC represents a straightforward, inexpensive and accurate method 
to study proteome changes between cell populations. SILAC-based MS has 
been used in wide variety of studies to answer scientific questions. It can be 
used to study protein-protein interactions, identification of phospho-substrates 
of kinases and phosphatases, membrane proteomics for biomarker 
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identification, as well as temporal dynamics for drug testing or induction of 
signaling pathways (Pandey A et al. 2000; Mann M et al. 2003).   
 
1.5.2. ERLIC fractionation 
After SILAC metabolic labeling, the cellular lysates from the two states were 
then combined and proteolytically digested by trypsin, and the resulting 
peptide mixture was subjected to efficient separation of the phosphorylated 
peptides from the non-phosphorylated counterparts using electrostatic 
repulsion-hydrophilic interaction chromatography (ERLIC) (Figure 1.15).  
The simultaneous usage of electrostatic repulsion and hydrophilic interaction 
in ERLIC results in peptide elution in an order of decreasing pI and increasing 
polarity (Hao P et al. 2010). The ERLIC profile will clearly demonstrate an 
early eluate containing the phospho-peptides, and a late but more abundant 
peptide population. The eluates collected were segregated into different 
fractions and systematically analyzed by tandem MS to increase detection rate 
of the low abundance peptides.  




1.6.  Leo1 and the PAF complex 
The multivalent PAF complex comprises of PD2/Paf1, Ctr9, Rtf1, 
Cdc73/Parafibromin and Leo1 (Figure 1.16), and additionally in humans, an 
unique interaction with the Ski8 complex (Zhu B et al. 2005). The PAF 
complex plays a fundamental role in transcription-related processes, and has 
been implicated in developmental diseases and cancer. 
 
 
Figure 1.16. Components of the PAF complex and their structural 
domains (Chaudhary K et al. 2007). 
 
The PAF complex was originally identified in yeast as an interacting partner 
of RNA polymerase II (RNAPII) (Krogan NJ et al. 2002). PAF complex acts 
as one of the major players in RNAPII-associated transcription initiation and 
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elongation, where the function of PAF complex was linked to its effects on 
histone modifications. PAF complex stimulates H2B mono-ubiquitination and 
pol II CTD phosphorylation, coupled with SET1 and SET2 recruitment, 
leading to histone H3 tri-methylation and remodeling of the chromatin (Figure 
1.17). It is also involved in other related gene expression processes such as 
transcription start site selection, and post-transcriptional mRNA quality 
control through regulated mRNA degradation (Pavri R et al. 2006).  
 
Through its transcriptional activation activities, the PAF complex is 
developmentally required to maintain normal embryonic stem cell (ESC) 
identity and self-renewal by modulating key pluripotency genes, and 
overexpression of the PAF complex blocks differentiation (Ding L et al. 
2009). Consistent with its role in development, deletion of 
Cdc73/parafibromin was reported to be embryonic lethal, leading to 
widespread tissue damage in adult mice (Wang P et al. 2008).  Recent 
advances in the understanding of this complex also revealed a role in cancer, 
whereby mutations or dysregulated expression of its subunits led to instability 
of the complex, resulting in aberrant gene expression. More relevantly, PAF 
complex was essential for MLL fusion proteins-related leukemogenesis by 
mediating Hox gene expression, maintaining a haematopoietic stem cell 
(HSC)-like signature and resistance to differentiation (Muntean AG et al. 
2010).  Interestingly, the subunits have opposing roles in cancers, acting as 




Figure 1.17. PAF complex-mediated H2B monoubiquitination for efficient 
transcription through chromatin (K Chaudhary et al. 2007). 
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1.7. Wnt/β-catenin in AML 
The canonical Wnt-β-catenin signaling cascade is a crucial regulator of adult 
stem cells biology (Reya T et al. 2005), and cancer cells hijack this signaling 
pathway, especially in colon carcinoma. In development, the canonical Wnt 
signaling pathway begins with the engagement of Wnt ligands with receptor of 
the Frizzled family and Lrp5/6. Under non-activation situation, adeomatous 
polyposis coli (APC) and axin bind to newly synthesised β-catenin, together 
with two kinases, CKI and GSK3. This multimeric complex, commonly 
known as the destruction complex, leads to the phosphorylation of multiple 
serine and threonine residues on the amino-terminus of β-catenin, targeting it 
for proteasomal degradation. On the other hand, with the activation of the Wnt 
receptors, axin is recruited to the intracellular domain of the Frizzled and 
activates a protein called Dishevelled that inhibits GSK3. As a consequence, 
β-catenin accumulates in the cytoplasm, and translocate to the nucleus where 
it interacts with the TCF/LEF transcription factors. This in turn regulates 




Figure 1.18. Canonical Wnt signaling cascade. In the presence of Wnt 
ligand and receptor activation, β-catenin translocates to the nucleus to activate 
Wnt target genes (Reya T et al. 2005). 
 
Aberrant activation of β-catenin is a common event in leukemia. For example, 
the acquisition of β-catenin in T-acute lymphoblastic leukemia cells resulted 
in elevated proliferation, survival and cell adhesion (Chung EJ et al. 2002). In 
addition, normal peripheral blood mononuclear cells do not express β-catenin, 
while β-catenin is abundantly found in leukemic cell lines and patient 
leukemic cells. In AML cells, the expression of β-catenin is associated with a 
higher activity of the TCF/LEF pathway, and activation of β-catenin target 




There are growing evidence that the Wnt pathway regulates self-renewal of 
hematopoietic stem cells and progenitors (Reya T et al. 2003; Reya T et al. 
2005; Simon M et al. 2005). Wnt proteins are produced by HSCs in the bone 
marrow niche where HSCs resides, and it was shown that HSCs are 
responsive to Wnt signaling in vivo (Reya T et al. 2003). Expression of a 
constitutively active β-catenin (S37A mutation) in normal CD34+ progenitor 
cells maintained the stem-ness of these cells with impaired differentiation 
(Simon M et al. 2005). Another report made an important finding that one of 
the signals involved in regulating HSC self-renewal is the β-catenin pathway. 
Through the transfection of constitutively active β-catenin into HSC (c-Kit+ 
Thy-1.1lo Lin-/lo Sca-1+ also known as KTLS fraction), β-catenin not only 
supported an immature state, but also expands HSC pool. Furthermore, these 
cells retained their ability to reconstitute the hematopoietic system, i.e. 
myeloid, T-cell and B-cell lineages in irradiated mice (Reya T et al. 2003).  
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1.8 Histone methylation in cancer 
In eukaryotic cells, DNA is packaged in the nucleus in a highly compact 
complex called the chromatin, which is further condensed to form the 
chromosome. The chromatin consists of 145-147 base pairs of DNA wrapped 
around an octamer that consists of two of each four core histones: H2A, H2B, 
H3 and H4 (Kornberg RD et al. 1999). The N-terminal tails of these structures 
are subjected to covalent modifications, such as methylation, which occurs on 
specific lysine and arginine residues. These modifications play a role in 
regulating gene expression and epigenetic memory, which influence cell 
identity. 
 
In recent years, histone methylation is widely studied since the identification 
of enzymes that catalyzes the addition (histone methyltransferases) and 
removal of methyl groups (histone demethylases) from histone tails. In 
general, methylation of H3K9, H3K27 and H4K20 are associated with 
transcriptional silencing, while methylation of H3K4, H3K36 and H3K79 are 
associated with transcriptional activation (Martin C et al. 2005). These 
modifications then act as docking sites on the DNA for other effector proteins 
to carry out the functional effects of the modification. 
 
There are two classes of histone demethylases, LSD demethylases and JMJC 
demethylases, with unique substrate specificities (Pedersen MT et al. 2010; 
Klose RJ et al. 2006). The activities of demethylases can be regulated through 
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their expression levels, recruitment to different target genes as determined by 
their domains or as part of protein complexes. Aberrant epigenetic alterations, 
caused by dysregulation of histone-modifying enzymes, can contribute to a 
variety of human cancers. For example, trimethylation of H3 (H3K9me3) is an 
important mark for heterochromatin. An increase in H3K9 methylation causes 
aberrant gene silencing in various human cancers, and dysregulation of 
H3K9me3 is associated with poor prognosis in gastric adenocarcinoma (Park 
YS et al. 2008) and acute myeloid leukemia (Müller-Tidow C et al. 2010). 
Overexpression of G9, a H3K9 dimethyltransferase, has been reported in 
breast, lung, liver, colon and prostate cancer (Huang J et al. 2010; Kondo Y et 
al. 2007, Kondo Y et al. 2008). On the other hand, JMJD2C (Jumonji C 
domain-containing 2C), a H3K9 demethylase, is overexpressed in cancer and 
contribute to genomic instability (Cloos PA et al. 2006). 
 
The JMJD2 histone demethylase family consists of four members, JMJD2A-
D. All four members contain the conserved JmjC and JmjN domains, which 
are the catalytic motifs of JMJD2 proteins. With the exception of JMJD2D, the 
other three members contain two Tudor and PHD domains, which are 
responsible for chromatin and transcriptional regulation. JMJD2 has been 
shown to harbour histone demethylase activity in vitro and in vivo on 




1.9. TF1-hPRL3 as our cell line model to study PRL-3 oncogenic activities 
in AML 
To assess the functions of PRL-3 in the pathogenesis of AML, our laboratory 
developed a pair of stable isogenic AML cell lines, TF1-pEGFP and TF1-
hPRL3 by transfecting pEGFP (vector control) and pEGFP-hPRL-3 vectors 
into TF-1 cells, respectively, followed by G418 selection and FACS sorting 
(Figure 1.19A). TF-1 is a cytokine-dependent AML cell line, and transforming 
events can render these cells cytokine-independent. qRT-PCR and western 
blot validated the overexpression of PRL-3 on both mRNA and protein levels 
in the TF1-hPRL3 cells relative to TF1-pEGFP cells (Figure 1.19B).  
 
In the absence of cytokines (human IL-3 or GM-CSF), the majority of TF1-
pEGFP cells became apoptotic after 72 hours. In contrast, most of TF1-hPRL3 
cells were viable (Figure 1.19C). TF1-hPRL3 cells not only resisted cytokine 
deprivation-induced apoptosis, but also proliferated well without additional 
cytokines (Figure 1.19C). Furthermore, methylcellulose assay showed only 
TF1-hPRL3 cells, but not TF1-pEGFP cells, formed colonies (Figure 1.19D). 
To determine the tumorigenic role of PRL-3 in vivo, we used the pair of TF-1 
cells in a subcutaneous mouse xenograft model. Strikingly, only TF1-hPRL3 
cells, but not TF1-pEGFP cells, formed tumor mass in immunodeficient mice 
(Figure 1.19E). The average TF1-hPRL3 tumor volume was 813 mm3 at 4 
weeks after cell inoculation (Figure 1.19E). Overall, these data suggest that 










Figure 1.19. Establishment and in vitro and in vivo. Characterization of 
TF1-pEGFP (vector control) and TF1-hPRL3 cell lines. (A) Images of 
TF1-pEGFP and TF1-hPRL3 cells in bright field and GFP channel under an 
invert microscopy. (B) qRT-PCR and western blot analysis of PRL-3 mRNA 
and protein expression in TF1-pEGFP and TF1-hPRL3 cells. β-actin was used 
as a loading control in the protein analysis. (C) After withdraw of human IL-3 
cytokine in the culture medium at 72 hours, TF1-pEGFP and TF1-hPRL3 cells 
were stained and assessed with Trypan Blue Exclusion methods on a 
hemacytometer. The percentages of viable cells at 72 hours were calculated 
relative to before IL-3 withdrawal (0 hour). To construct the cell growth curve, 
20 x 105 TF1-hPRL3 cell were initially seeded in standard medium without 
additional human cytokines. Cells were counted and reseeded in fresh medium 
every two days for up to 6 days. In both figures, three independent replicates 
were conducted (mean ± SD).  (D) Colony forming assay (CFA) of TF1-
pEGFP and TF1-hPRL3. The experiments were duplicated and representative 
pictures are presented. (E) Mouse xenograft models of TF1-pEGFP and TF1-
hPRL3. Five million TF1-pEGFP and TF1-hPRL3 cells were subcutaneously 
injected into loose skin between the shoulder blades and the left and right front 
leg of NOD/SCID recipient mice, respectively. At 4 weeks after injection, 
tumors were harvested and measurement of tumor volume was taken. The 
tumor volume is shown as the mean ± SD (mm3). Arrows indicated the TF1-
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hPRL3 tumor mass at right and no tumor at left (TF1-pEGFP cell injected site) 
in one mouse.  **p<0.005. 
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1.10. Aims of research 
The work performed on defining the roles of PRL-3 have significantly 
improved our understanding of how this phosphatase contributes to cancer 
progression. However, our knowledge of the direct physiological and 
pathological substrates of PRL-3 is still limited. To date, comparative 
proteomic analyses on PRL-3 overexpression in solid tumor cell lines have 
been examined using various methodologies, such as one-dimensional (1D) or 
two-dimensional (2D) gel electrophoresis coupled with mass spectrometry 
(MS) analyses. However, these approaches were insensitive and 
irreproducible. Furthermore, in addition to differential protein expression, 
phosphorylation events are also important to comprehend signaling networks 
downstream of PRL-3. We created the TF1-hPRL3 cell line as a stable cell 
line model to study PRL-3 signaling in AML. Our in vitro data demonstrated 
that ectopic PRL-3 expression in the factor-dependent TF-1 AML cells confers 
cytokine-independent growth, induces colony-forming ability in 
methylcellulose media and tumorigenesis in vivo, making it an ideal model for 
PRL-3 downstream studies.  
 
The aim of this study is to employ SILAC-based MS to identify PRL-3 
induced changes on a system-wide view. Using this approach, we identified 
Leo1 as a key target of PRL-3 phosphatase. We sought to examine the 
association between PRL-3 and Leo1 expression in multiple AML cell lines 
and primary patient samples to determine the significance of this relationship, 
and how PRL-3 acts as an upstream regulator of Leo1. Using Leo1 
knockdown systems, we aim to determine whether abrogation of Leo1 is 
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sufficient to reverse the oncogenic activities conferred by PRL-3 
overexpression. We are also interested to dissect the mechanisms downstream 
of Leo1 in oncogenesis, whether it functions alone or as part of the PAF 
complex.  
 
In addition, Leo1 displayed a serine dephosphorylation status in our MS 
analysis. Therefore, we will also validate Leo1 as a direct substrate of PRL-3 
phosphatase activity. Furthermore, we will attempt to identify the specific 
phosphosites of Leo1 that were modulated by PRL-3. It has been reported that 
Leo1 can co-immunoprecipitate with β-catenin, and 
phosphorylation/dephosphorylation of proteins was known to affect binding 
affinity towards their interaction partners. Hence, we are also interested to 
determine whether PRL-3 mediated dephosphorylation of Leo1 affects β-

















Full-length human PRL-3 cDNA cloned in pEGFP-C1 vector, tetracycline-
inducible pSTAR vector and pGEX-KG1-PRL3 plasmids were kind gifts from 
Dr Zeng Qi (A-star, IMCB). Catalytically-inactive PRL-3 mutants, namely 
PRL3/C104S, PRL3/D72A and PRL3/C104S/D72A, were generated using 
QuikChange XL Site-Directed mutagenesis kit (Strategene). The QuikChange 
XL method uses PfuTurbo DNA polymerase to generate the mutant double-
stranded DNA vector with high fidelity, and subsequent transformation into 
XL10-Gold Ultracompetent cells followed by blue-white colony screening. 
All point mutations were verified by DNA sequencing.  
 
The expression vector for human Leo1 was purchased from Centrogen, and 
tagged with FLAG. The PRL3 shRNA and Leo1 shRNA clones were 
purchased from Sigma-Aldrich Mission TRC shRNA library. The shRNA 
sequences directed against JMJD2A, JMJD2B, JMJD2C and JMJD2D were 
obtained from Mission TRC shRNA library, cloned into pLKO.1 vector 
(Sigma-Aldrich) at EcoRI/AgeI sites and verified by DNA sequencing. Stable 
knockdown cell lines were achieved using appropriate concentrations of 
puromycin selection (Calbiochem) depending on the cell line. The entire 
coding sequence of human JMJD2C was amplified from 293 cDNA and 
cloned into the Kpn1/Xho1 sites of pcDNA4/Myc-His (Invitrogen). All 
constructs were verified  by sequencing. 
 
Primers containing restriction sites for Kpn1/Sma1 was used to amplify Leo1 
full-length promoter from genomic DNA extracted from 293T cells. The 
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fragments amplified using PCR were double-digest and cloned into the 
SmaI/XhoI sites of the pGL3-basic firefly luciferase vector (Promega) and 
confirmed by sequencing. 
 
2.2. Antibodies 
Anti-PRL3 (clone 318) was a kind gift from Dr. Zeng Qi. Anti-Leo1, anti-
Paf1, anti-Cdc73 and anti-Ctr9 antibodies were from Bethyl Labs; anti-actin, 
anti-hnRNPE1, anti-HSP90, anti-JMJD2C, anti-c-Myc (9E10), anti-lamin A 
and anti-GFP antibodies were from Santa Cruz; anti-Stathmin, anti-HDAC2, 
anti-tubulin, anti-cyclin D1, anti-cyclin A, anti-cyclin B1,  anti-histone 3, anti-
H3K9me2, anti-H3K27me2, anti-H3K27me3, anti-H3K4me1, anti-H3K4me2, 
anti-H3K4me3 and anti-H3K79me2 antibodies were from Cell Signaling; anti-
H3K9me3 antibody was from Active Motif; anti-Flag antibody was from 
Sigma-Aldrich; anti-β-catenin was from BD Biosciences; anti-ABC and anti-
phospho-serine,  anti-phospho-tyrosine (4G10), and anti-phospho-threonine 
were from Millipore; anti-phospho-Leo1 (S10) and anti-phospho-Leo1 (S551) 
antibodies were from Abgent. 
 
2.3. Cell culture and cryopreservation of cell lines 
HEK293T and HEK293T/17 cells were cultured in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal calf serum (FCS). TF-1 and 
TF1-derived stable transfectants, TF1-hPRL3, were cultured in RPMI 1640 
medium containing 10% FCS and supplemented with 5ng/mL human 
interleukin-3 or human GM-CSF (Miltenyi Biotec). TF1-hPRL3 cell line was 
created through transfection of GFP-tagged full-length human PRL-3 cDNA 
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constructs into TF-1 cells, and selected for neomycin-resistant clones followed 
by fluorescence-activated cell sorting (FACS) for GFP-positive cells. Molm-
14, HEL and HL-60 leukemic cell lines were cultured in RPMI 1640 medium 
containing 10% FCS. Human CD34+ cells were grown in StemSpan SFEM II 
medium (StemCell Technologies) supplemented with StemSpan CC100 
cytokine cocktail (StemCell Technologies) to a final concentration of 
100ng/ml recombinant human Fms-like tyrosine kinase 3 ligand, 100ng/ml 
recombinant human stem cell factor, 20ng/ml recombinant human interleukin-
3 and 20ng/ml recombinant human interleukin-6. Primary AML cells were 
grown in same conditions, except with the additional supplementation of GM-
CSF to a final concentration of 20ng/ml. In certain cases, primary leukemic 
cells were thawed and immediately lysed to obtain cell lysate.  
 
Cell lines were maintained in culture for less than 25 passages. Frozen vials 
were removed from liquid nitrogen tank  (-196°C) and thawed at 37°C for 5 
minutes before washing with 5mL of room temperature 1 x PBS. Cells were 
spun down at 1200rpm for 5 minutes and cell pellets were resuspended with 
fresh complete media and seeded into T25 flasks. Cells were grown for 1 week 
before experiments were conducted to ensure log-phase growth. To freeze 
down cells for cryogenic preservation, cell suspension was spun down at 
1200rpm for 5 minutes. Cell pellets were then resuspended with freezing 
media (95% culture media and 5% DMSO) and aliquoted 1ml of 2x106 cells 
into each cryovials. Vials were placed in Mr. Frosty cylinder (Nalgene) filled 
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with 100% isopropanol and kept at 80°C freezer. Severals days later, vials 
were transferred to liquid nitrogen tank for long-term cryopreservation. 
 
2.4. SILAC-based Mass Spectrometry 
TF-1 cells were cultured in "light" SILAC medium containing the normal 
lysine and arginine amino acids, while the TF1-hPRL3 cells were grown in 
"heavy" SILAC medium with stable isotope-labeled 13C6 lysine (+6-Da shift) 
and 13C615N4 arginine (+10-Da shift) (Thermo Scientific). Cells were grown in 
media supplemented with 5ng/mL human interleukin-3, and starved for 16 
hours before harvest. The cellular lysates were combined and proteolytically 
digested by trypsin, separation of the phosphorylated peptides using ERLIC, 
followed by tandem MS identification as previously described (Hao et al. 
2010). To ensure high confidence and quality identifications, we subjected our 
peptides to target-decoy database search strategy with a false discovery rate 
(FDR) of less than 1% (<1%). Differential protein expression and 
phosphorylation were quantified from the relative intensity ratios in the MS 
spectra between the "heavy" and "light" states.  
 
2.5. Transfection and Virus infection 
High-titer lentiviruses were produced in HEK293T/17 cells by transfection 
using JetPrime (Polyplus) with packaging vectors psPAX2 and pMD2.G 
together with the respective shRNAs constructs. Virus was harvested at 48 and 
72 hours after transfection, pooled and concentrated by centrifugation 
(Amicon). Aliquots of virus, together with 8µg/mL of polybrene, were used to 
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infect leukemia cells by the spin-infection method. Briefly, cells and the virus 
were centrifuged at 2500rpm for 90 minutes at room temperature, washed and 
resuspended in medium for continued culturing. Knockdown effects were 
determined at 72 hours after infection by either qRT-PCR or western blotting.  
In some cases, the cells were selected in appropriate concentrations of 
puromycin for seven days to create stable knockdown cell clones.  
 
Transient transfection experiments in 293T cells were performed using 
JetPrime according to manufacturer's instructions. Protein lysate was obtained 
48 hours after transfection. 2 x 106 of Molm-14 and HEL cells were seeded 
into 6-well plate, and transfected with 2µg of shRNA vector using the Lonza 
Nucleofector system (Kit V). 1 x 106 TF-1 cells were seeded into 6-well plate, 
and transfected with 1µg of shRNA using the Neon system (Life 
technologies). Cells were harvested at 24 hours for mRNA or 48 hours for 
protein extraction. 
 
Primary leukemia cells were transfected using nucleofection (Lonza), kit T. 
Cells were pulsed with two different programs (U-15, S-04) and analyzed 24 
hours later. For siRNA transfection, 2 x 105 cells were seeded per well in a 6-
well format, and 1µg siRNA was used for transfection unless otherwise stated.  
 
2.6. RNA extraction, cDNA conversion and quantitative Real-time PCR 
Total RNA was isolated using RNeasy Kit (Qiagen). Cells were pelleted 
down, and 1mL Trizol (Invitrogen) was added to lyse the cell pellet, followed 
by the addition of 200µL chloroform and centrifugation at 12,000rpm for 15 
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minutes at 4ºC to separate RNA, DNA, and proteins from other cell contents. 
The top liquid phase containing RNA was then transferred to fresh eppendorf 
tube followed by addition of 70% ethanol. The samples were transferred to the 
RNA column to allow RNA binding by centrifugation at 12,000rpm for 30 
seconds. Columns were washed once with 750µL RW1 buffer and twice with 
500µl RPE buffer. Finally, RNA was eluted with 20µL RNAse-free water. 
RNA concentration and purity were assessed using Nanodrop ND-1000 using 
1µL of each sample. 
 
0.5-1µg of RNA was reverse transcribed using iScript Reverse Transcription 
Supermix (Biorad) using oligo (dT) primers for complete RNA coverage. 
Briefly, RNA samples were added with 4µL of Script Reverse Transcription 
Supermix, and topped up with nuclease-free water to a final volume of 20µL. 
The reaction mix was incuabated in thermo cycler running for 5 minutes at 
25ºC, followed by 30 minutes at 42ºC and 5 minutes at 85ºC. 
 
Quantitative PCR (qPCR) was performed using 2x SYBR Green supermix 
(Biorad) on an ABI 7300 Real-time PCR machine (Applied Biosystems). 1-
2µL of cDNA were added together with 0.8µL gene-specific primer mix 
(10µM) to 10µl of 2X master mix, and topped up with nuclease-free water to a 
final volume of 20µL. Measured transcript levels were normalized to β-actin 
housekeeping gene. Calculations were based on the ∆∆Ct method employing 
β-actin gene for normalization. Samples were run in triplicates. Primer 




2.7. Chromatin immunoprecipitation (ChIP) 
ChIP assays were performed using H3K9me2, H3K27me3, H3, H3K9me3, 
and JMJD2C antibodies. 5-10 x 106 cells were cross-linked with formaldehyde 
(final concentration, 1%) for 10 minutes, and cross-linking was terminated by 
adding glycine to a final concentration of 0.125M. A two-step lysis was 
performed to extract the DNA fraction. The cells were first resuspended in 
Farnham lysis buffer (5mM PIPES pH 8.0, 85mM KCl, 0.5% NP-40, 1x 
protease inhibitor) for 15 minutes, and spun down at 800g for 5 minutes to 
collect the nucleus. The pellet was then suspended in RIPA lysis buffer (1% 
NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1x protease inhibitor), spun 
down at 12,000g for 20 minutes. The collected supernatant was then sonicated 
to generate DNA fragments of sizes between 100bp to 300bp as determined by 
titration. Sonication was performed as follows: 30 seconds pulse on and 30 
seconds pulse off for 4 cycles. The entire sonication process was performed on 
ice to reduce heat generation. The respective antibodies were incubated with 
the sheared chromatin at 40C overnight, and immunoprecipitated using Dyna 
Protein G magnetic beads (Invitrogen). The recovered beads were washed 
using the following buffers (with 0.2mM PMSF added to minimize 
degradation) for 3 minutes with rotation, followed by recovery of beads using 
the magnetic stand. First wash was performed with 0.1% SDS buffer, second 
wash with 0.1% SDS/ 0.35M NaCl, third wash with LiCl/NP-40 and final 
wash with TE buffer. For the last step, DNA was eluted in 100µL of ChIP 
elution buffer containing proteinase K. Samples were heated at 620C for 2 
hours with shaking at 400rpm. Finally, samples were heated at 950C for 10 
minutes. Clean-up of DNA was done using QIAquick PCR purification kit 
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(Qiagen). qPCR was performed using the eluted DNA (sample) and 1% input. 
The % input was calculated as described previously (Muntean et. al., 2010) 
after normalization with amplification from negative control primers. Primer 
sequences were listed in the table below (Table S3).  
 
2.8. Protein extraction and Western Blot  
Log-phase cells were harvested, wash twice in ice-cold phosphate buffered 
saline (PBS) and lysed with appropriate volume of RIPA lysis buffer (50mM 
Tris-HCl pH7.4, 1mM EDTA, 150mM NaCl, 0.5% sodium deoxycholate, 
1mM Na2VO4, 20mM NaF, and Complete protease inhibitor cocktail 
(Roche)). Samples were incubated on ice for 30 minutes, and vortexed for 15 
seconds every 15 minutes. After which, the samples were centrifuged at 
16,000rpm for 15 minutes. The supernatant was immediately transferred to 
fresh eppendorf tubes. The lysate concentration was measured using BCA 
assay (Thermo Scientific) according to manufacturer’s instructions using 1µL 
of lysate. Equal amounts of lysate were resolved by 10-16% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to the sizes 
of protein of interest, and subjected to immunoblotting. Running of gel was 
typically performed at 80-120V constant voltage, while transfer was 
performed at 100V constant voltage in the cold room. The respective primary 
antibodies were used to probe the membranes at 40C overnight, followed by 
detection with the secondary antibodies tagged with horse radish peroxidase 




Nuclear and cytoplasmic fractionation was performed using NE-PER 
Fractionation Kit (Thermo Scientific) following manufacturer’s protocol using 
10 million fresh cells for each experiment. To test the extracts for 
contamination between nuclear and cytoplasmic fractions, we probed with 
Lamin A and Tubulin, which probes for nuclear and cytoplasmic fractions, 
respectively. 
 
2.9. Co-Immunoprecipitation (co-IP) 
293T cells were transiently transfected with GFP-tagged PRL-3, PRL3/C104S, 
PRL3/D72A or PRL3/C104S/D72A mutants, and RIPA lysates were collected 
48 hours later. Samples were precleared with A/G agarose beads for 1 hour 
with rotation at 4ºC. 1mg of lysate were used for immunoprecipitated with an 
anti-GFP antibody (Santa-Cruz) for 2 hours at 40C with 360-degree rotator, 
followed by the addition of 20µL of A/G agarose beads (Santa-Cruz) for 1 
hour with rotation. Beads that contained the immunoprecipitated samples were 
washed thrice with RIPA buffer, followed by centrifugation at 2500rpm for 5 
minutes after each wash. Immunoprecipitates were eluted with 20µL of 2x 
SDS loading buffer and separated using SDS-PAGE. 
 
For endogenous IP, 1.5mg of lysate was used with 2-5µg of primary antibody 
and incubated for 2 to 4 hours at 4°C. 20µL of A/G agarose beads (Santa-
Cruz) was then added and incubated for another 1 hour with rotation. 
Immunoprecipitates were collected by centrifugation at 2,500rpm for 5 
minutes at 4°C, and washed trice with RIPA buffer before proceeding with 
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SDS-PAGE. Depending on the species in which the primary antibody was 
raised, rabbit or mouse IgG was used as control. 
 
2.10. Luciferase assay 
1.5µg of firefly reporter, 30ng of internal control Renilla luciferase, together 
with various PRL-3 and JMJD2C expression constructs were transfected into 2 
X 105 293T cells seeded in 6-well plates using Jetprime reagent. Dual-
luciferase assay (Promega) was performed at 48 hours post-transfection 
following manufacturer’s protocol. Briefly, cells were harvested using 500µL 
of lysis buffer provided, and allowed to lyse at room temperature for 15 
minutes. 20µL of the lysate was added to LAR II solution in a 1.5mL 
eppendorf tube, and firefly luciferase reading was measured. 100µL of 
Stop&Glo reagent was then added, and renilla luciferase activity was 
measured. Relative luciferase activity is plotted as firefly/Renilla luciferase 
readings. Reading was performed using a single-injector luminometer 
(Promega Glomax).  
 
2.11. Glutathione S-transferase (GST) Pull-down assay 
pGEX-KG1, pGEX-KG1-PRL3 or pGEX-KG1-C104S constructs were 
transformed into DH5ɑ cells and grown to log-phase growth. 0.1mM of ITPG 
was then added to bacterial culture for another 4 hours to induce expression of 
glutathione S-transferase (GST) fusion proteins. The bacteria was pelleted, 
and sufficient cold lysis buffer was added. Bacteria was lysed on ice using the 
sonication method of 4 rounds of 25 seconds burst with 1 minute resting 
intervals. Triton X-100 was added to a final concentration of 1%, and protein 
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lysate was collected by centrifugation of 15,000g for 20 minutes. Lysate was 
filtered through 0.45 µM filter immediately before GST pull-down. 
Purification of GST fusion proteins was performed using GSTrapFF 1mL 
columns (GE Healthcare). Lysate was passed through column containing 
glutathione-agarose using a peristaltic pump, washed with binding buffer 
(PBS, pH 7.3 (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.3) and elute under mild, non-denaturing conditions (50 mM 
Tris-HCl, 10 mM reduced glutathione, pH 8.0). The eluate was boiled in SDS 
loading buffer, separated by SDS-PAGE and visualized using Commassie 
Blue staining. 
 
2.12. In vitro dephosphorylation assay 
Endogenous Leo1 protein was immunoprecipiated using Leo1 antibody from 
Molm-14 cells, and used as substrate for the in vitro dephosphorylation assay. 
GST,  PRL3-GST (0.5 or 1µg) or C104S-GST (0.5 or 1µg) were added to the 
Leo1 substrate in 20µL dephosphorylation buffer (50 mM Tris pH 7.5, 2 mM 
DTT, 1 mM MgCl2, 0.1 mM MnCl2) at 300C for 30 minutes. Loading buffer 
was added and sample was boiled for 5 minutes, separated by SDS-PAGE and 
probed with Leo1 or phospho-serine antibodies.  
 
2.13. Immunofluorescence 
Cells were immobilized on slides using the cytospin method and fixed with 
4% paraformaldehyde for 20 minutes at room temperature, followed by 
permeabilization with 0.2% Triton X-100 in PBS for 20 minutes, and blocking 
with 10% FBS in 1x PBS for 1 hour. After incubation with anti-Leo1 (1:250, 
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rabbit) and anti-PRL3 (1:50, mouse) primary antibodies for 1 hour at room 
temperature, the slides were thoroughly rinsed with cold 1x PBS and 
incubated with goat anti-rabbit (1:50, Alexa Fluor 488) or goat anti-mouse 
(1:50, Alexa Fluor 594) for 1 hour in the dark. The cells were counterstained 
with 4', 6-diamidino-2-phenylindole (DAPI), and mounted with FluorSave 
reagent (Calbiochem). Fluorescence was observed using microscope 
(Olympus TH4-200). 
 
2.14. Cell proliferation 
Cell proliferation was determined by the CellTitre-Glo Assay (Promega) 
according to the manufacturer's instructions. Cells were washed with 1x PBS 
and re-seeded to 2 x 105 cells per mL in 96-well plate format, and 100µL of 
cell suspension was dispensed per well. Equal volume of reagent were added 
to the cells at each time point, and incubated for 10 minutes in the dark before 
reading was recorded by luminescence (Tecan infinite M200). Assay was 
performed in independent triplicates over 4 days, and the mean values were 
used to plot the graph. Medium without cells was used to determine 
background luminescence. 
 
2.15. Colony-formation assay 
Cells were harvested and washed twice with 1x PBS before resuspending at 
1000 cells in 2mL MACS HSC-CFU media containing human GM-CSF 
(Miltenyi Biotech). Cells were cultured for 7 to 14 days in 6-well plate format 





2.16. Apoptosis assay 
For apoptosis, 1 x 106 cells were washed with 1 x PBS and stained with 
Annexin V-FITC and propidium iodide (PI) (BD Pharmingen) for 15 mins in 
the dark according to manufacturer instructions. Cells were passed through a 
cell mesh or strainer to obtain single cells before analysis with LSRII Flow 
Cytometer (BD Biosciences).  
 
2.17. Cell-cycle analysis 
Cells were washed in 1x PBS once before resuspending 1x 106 cells in 0.5mL 
of ice-cold 1x PBS. In a drop-wise manner, add the cells into 4.5mL of ice-
cold 70% ethanol. Allow the cells to fix for at least 24 hours at 40C.  Prior to 
flow cytometry analysis, centrifuge the cells to collect cell pellet and wash 
with 1x PBS to remove traces of ethanol. Stain with PI for 15 to 30 minutes 
and analyze. 
 
2.18. Double thymidine and nocodazole treatment  
Cells were seeded at a concentration of 5x 105/mL in a total of 20mL R10. 
Thymidine is used at a final concentration of 2mM (stock of 10 mM), and 
used to treat  cells for 16 hours. Cells were then washed twice with 1x PBS, 
and resuspended in 20mL of R10 for 7 hours. This releases the cells into cell 
cycle. 2mM thymidine is then added to the medium again after 7 hours, which 
is the second thymidine block. The cells were blocked for 16 hours this time 
and counted at the end of second thymidine block. Cells were then washed 
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twice with 1x PBS, and resuspended at a concentration of 5x 105/mL. 
50ng/mL of nocodazole (stock of 5 mg/mL) is added, and an aliquot of cells 
are collected at time points 0 h, 3 h, 5 h, 7 h and 24 h. Cells either used for 
FACS analysis after fixing in 70% ethanol, or used for western blot. The cell 
density, concentration of chemicals used and treatment durations are 
optimized for the cell line Molm-14 and HL-60. 
 
2.19. Processing of human peripheral blood 
10mL of peripheral blood from normal individuals were collected as per 
guidelines. The blood was pooled into a 50mL Falcon tube, and centrifuge at 
3000rpm, 10 minutes. The top layer, which is plasma, was discarded. The 
bottom layer contains the red and white blood cells. 45mL of ACK lysis buffer 
is added to 5mL of the cells, mixed well by inverting, and lysis was performed 
at room temperature for 10 minutes. The cells were centrifuged at 3000rpm for 
10 minutes, and the top layer was discarded. The cell pellet is re-suspended in 
another 45mL of ACK lysis buffer for second lysis at room temperature for 10 
minutes. The cells are collected by centrifugation at 3000rpm for 10 minutes. 
The cell pellet is re-suspended in an appropriate volume of RPMI 1640 based 
on the size of the cell pellet. Usually, 3 to 5mL of RPMI 1640 is added. If 
debris is present, the cell suspension can be passed through a 70µM cell 
strainer. 20µL of the cell suspension is used to do cell count to calculate the 
amount of white blood cells isolated.  
 
2.20. Sorting for T, B and myeloid cell populations 
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The cells were washed in cold 1x PBS, and transferred to sterile FACS tubes. 
Tubes were prepared in the following manner: 800,000 cells for single stain 
(for gating purposes), and the rest of the cells for sorting. Cells were 
centrifuged at 1500rpm for 5 minutes to form pellet. Blocking is performed 
using mouse serum to re-suspend cells, on ice for 15 minutes. After blocking, 
the appropriate volume of antibody was added accordingly to the amount of 
cells. The cells were triply-stained with CD33-APC (BD Biosciences), CD3-
FITC (BD Biosciences) and CD20-PE (BD Biosciences), for myeloid, T and B 
cell populations respectively. The cells were stained for 30 minutes on ice, 
protected from light. After staining, the cells were washed with cold 1x PBS. 
Cell pellet was resuspended in viability dye, Hoescht 33342 (Calbiochem), 
and analyze by flow cytometry (FACSAria).  
 
2.21. Statistical analysis 
Statistical analyses of the bar graphs were performed using Prism (GraphPad 
software Inc.). Student t-tests were carried out on experimental readings to 
generate p-value for pairwise comparisons. Experiments with error bars are 
performed in triplicates and mean value was shown. 
 
2.22. Gene Ontology analysis 
Proteins that were differentially expressed with at least two-fold differences 
between TF1-EGFP and TF1-hPRL3 were separated into upregulated and 
downregulated proteins. The upregulated proteins set was then imported into 
DAVID (http://david.abcc.ncifcrf.gov/) and Ingenuity Pathway Analyses 
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(IPA) software for gene ontology analysis. From the analysis, signaling 














CHAPTER 3: PROTEOMIC PROFILING IDENTIFIES LEO1 AS A 





3.1. Global phosphoproteomic changes in TF1-hPRL3 cells 
To get an overview of the phosphoproteomic changes mediated by PRL-3 
phosphatase, we first probed the total serine, threonine and tyrosine 
phosphorylation levels in cytokine-starved TF-1 parental and TF1-hPRL3 
cells. Significant changes in the global phosphoproteomic patterns can be 
clearly seen in TF1-hPRL3 cells versus the TF-1 cells, notably with the 
phospho-threonine and phospho-serine antibodies (Figure 3.1). Detection with 
the phospho-amino acid antibody which recognizes all serine-, threonine- and 
tyrosine-phosphorylated proteins reveals that PRL-3 reduced the overall 
appearance of the phospho-proteins especially around the 37-50kDa region. Of 
special note, a 100kDa phosphothreonine-containing protein barely apparent 
in the TF-1 cells showed up after PRL-3 overexpression, and PRL-3 also 
induced significant threonine phosphorylation on a protein size about 75kDa. 
This suggests that although the phospho-protein levels were decreased at the 
overall level, selective increases in threonine phosphorylation can be observed 
on the individual proteins. Since PRL-3 is a phosphatase, increases in 
phosphorylation levels of its substrates can be explained by the 
dephosphorylation of a negative regulator, thus increasing phospho-threonine 
levels. Differential phospho-serine immunoblotting can be observed on a 
number of proteins across different sizes, while phospho-tyrosine 
immunoblotting reveals fewer protein bands. This is in line with the overall 
distribution of phospho-serine, threonine and tyrosine, where phosphorylation 
on tyrosine residues can only be detected on less than 2% (<2%) of all cellular 







Figure 3.1. Global phosphoproteomic changes induced by gain of PRL-3 
expression in TF-1 cells. The cell lines were starved from human IL-3 for 16 
hours before harvesting the whole cell lysate. Anti-phosphamino acids, 
phosphoserine, phosphothreonine and phosphotyrosine levels were compared 
using 30µg of lysate from TF-1 and TF1-hPRL3 cells with the respective 




3.2. Screening for PRL-3 targets by SILAC-MS 
To comprehensively elucidate the pathological targets and activated 
phosphorylation events downstream of PRL-3, we performed a large-scale 
quantitative study by combining SILAC metabolic labeling, phosphopeptide 
enrichment and high-accuracy mass spectrometry (MS) approaches. This 
strategy allow us to determine both the proteomic and phosphoproteomic 
changes induced by PRL-3 expression. To directly compare the differences 
between the TF-1 parental and TF1-hPRL3 cells, we differentially labeled the 
cells using stable isotope labeling by amino acids in cell culture (SILAC). TF-
1 cells were cultured in "light" medium containing the normal lysine and 
arginine amino acids, while the TF1-hPRL3 cells were grown in "heavy" 
medium with stable isotope-labeled 13C6 lysine (+6-Da shift) and 13C615N4 
arginine (+10-Da shift) analogs (Figure 3.2A) until full incorporation. The two 
cell populations are distinguishable by MS after labeling, which allows all 
downstream processing steps to be performed together. Thus, SILAC 
represents a method to accurately compare changes between two cell 
populations. 
 
The cellular lysates from the two states were then combined and 
proteolytically digested by trypsin, and the resulting peptide mixture was 
subjected to efficient separation of the phosphorylated peptides from the non-
phosphorylated counterparts using electrostatic repulsion-hydrophilic 
interaction chromatography (ERLIC). The ERLIC profile clearly demonstrates 
an early eluate containing the phospho-peptides, and a late but more abundant 
peptide population (Figure 3.2B). The eluates collected were segregated into 
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52 fractions and systematically analyzed by tandem MS to increase detection 
rate of the lower abundance peptides. To ensure high confidence and quality 
identifications, we subjected our peptides to target-decoy database search 
strategy with a false discovery rate (FDR) of less than 1% (<1%). Differential 
protein expression and phosphorylation were quantified from the relative 
intensities ratios in the MS spectra between the "heavy" and "light" states.  
 
We obtained measurements of 2291 peptides corresponding to 803 proteins 
harbouring 1163 phosphorylation sites. We identified a total of 398 proteins 
whose expression was significantly perturbed after PRL-3 overexpression, 
with 331 proteins upregulated (>1.5-fold), and 67 proteins downregulated 
(<0.6-fold) (Figure 3.2C), suggesting that PRL-3 both activates and represses 
protein expression. More importantly, PRL-3 alters the phosphorylation status 
on 192 proteins (Figure 3.2C). Specifically, 354 phosphopeptides showed 
increased phosphorylation (>1.5-fold) and 40 showed decreased 
phosphorylation (<0.6-fold). Among the phosphosites, we identified 79% 
phosphoserine, 17% phosphothreonine and 2% phosphotyrosine (Figure 
3.2D). This is similar to previous classical reports of the distribution of serine, 
threonine and tyrosine, therefore reflecting the validity of our global 
phosphopeptide enrichment strategy. To date, this is the largest reported 
dataset for proteins that are regulated by PRL-3. 
 
To gain a functional understanding of the dataset, we subjected the different 
protein clusters (up- or down-regulated) to biological processes, molecular 
functions, cellular components and pathway analysis tools. Gene Ontology 
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(GO) analysis of the upregulated proteins revealed novel biological processes 
of PRL-3 such as nucleic acid metabolism (19.7%), protein metabolism 
(15.1%) and pre-mRNA processing (5.7%), as well as validated involvement 
in cell-cycle regulation (7.1%) and cell motility (6%) as depicted in Figure 
3.2E. GO term analysis also placed the upregulated proteins into different 
molecular functions, and factors involved in nucleic-acid binding were 
significantly enriched (p<0.0001). Other enriched molecular functions 
included chaperones, RNA-binding proteins, mRNA processing factors, and 
chromatin binding proteins. Amongst the differentially-regulated proteins, 
45.5% of them are nuclear proteins while 54.5% are cytoplasmic proteins 
(Figure 3.2F). Previously reported to function mainly in the cytoplasm, PRL-3 
appears to affect nuclear proteins to a large extend, implicating a novel 
involvement of PRL-3 in nuclear activities.  
 
In conclusion, our quantitative large-scale profiling of cellular protein changes 
resulting from elevated PRL-3 expression provided a broader understanding of 
PRL-3 mediated signaling pathways and novel mechanisms of oncogenesis 

































Figure 3.2. Schematic overview of SILAC approach and data analysis. (A) 
TF1-EGFP or TF1-hPRL3 cells were grown in “light” and “heavy” SILAC 
medium respectively, and cells were deprived from hIL-3 for 16 hours before 
harvest. The lysates were combined and proteolytically digested with trypsin. 
The tryptic peptides were separated by ERLIC chromatography before MS 
identification. (B) ERLIC profile showing an early and late eluate. (C) 
Summary of MS dataset. Proteins were categorized based on the Heavy:Light 
ratio (TF1-hPRL3:TF1) in abundances and phosphorylation levels. 
Upregulation is defined as a ratio change of >1.5, while downregulation is 




(pS, pY and pT) detected by our MS were compared to previous reports. (E) 
Gene Ontology analysis of the overexpressed proteins using DAVID. The top 
five significantly over-representated biological process clusters were shown. 
(F) Gene Ontology analysis based on cellular localization of the differentially-




3.3. MS analysis identifies Leo1 as the most differentially regulated 
protein by PRL-3 
Our proteomics profiling by SILAC identified several reported targets of PRL-
3 (Figure 3.3A), as well as novel targets of PRL-3 specifically implicated in 
leukemia. Unexpectedly, we did not detect PRL-3 in our MS. When we 
probed into the amino acid sequences of PRL-3, we found that trypsin do not 
fragment PRL-3 sufficiently, generating peptides that are either too long or 
short for ideal detection with MS. Nonetheless, PRL-3 overexpression was 
confirmed at the protein level (Figure 3.3B). Leo1 emerged as the top 
candidate from the Mass Spectrometry (the list of proteins can be found in 
Table S1 in Appendix section) 
 
For this study, we focused on the upregulated candidates, since they are likely 
to be useful as potential therapeutic targets and biomarkers in PRL-3 positive 
cancers. First, we verified the MS dataset using western blot. Expression of 
several representative proteins, including Leo1, stathmin, HSP-90, hnRNPE1 
and HDAC2 were compared between TF-1 parental and TF1-hPRL3 cells 
(Figure 3.3B), and concordance was observed between the western blot and 
MS results. Using a reverse strategy to validate the candidates, as well as to 
exclude the possibility of TF1-specific effects, we performed lentiviral-based 
delivery of PRL-3 shRNA into two human AML cell lines, Molm-14 and 
HEL, which expresses high endogenous PRL-3. High infection rates were 
obtained leading to a clear reduction of PRL-3 to undetectable levels in both 
cell lines (Figure 3.3C), and the same panel of proteins was investigated. In 
agreement with the up-regulated effects seen with PRL-3 overexpression, 
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knockdown of PRL-3 reduced the levels of Leo1, stathmin, HSP90 and 
hnRNPE1 (Figure 3.3C). An exception was HDAC2, where although MS 
identifies it as one of the upregulated proteins by PRL-3, western blot was not 
sensitive enough to detect the differences. These experiments confirmed that 
these proteins were the true targets of PRL-3 in leukemia.  
 
Leo1, component of the human polymerase II-associating factor 1 (PAF) 
complex, was the top candidate from the MS analysis with the most significant 
increase in protein abundance. Recent articles have also implicated the PAF 
complex in stem cell pluripotency, oncogenesis and MLL-mediated 
leukemogenesis. Given the novel implication of Leo1 as a potential target of 
PRL-3, and the importance of the PAF complex in cancer, we chose to focus 
on Leo1 for the current study.  
 
To confirm that Leo1 is specifically up-regulated by PRL-3, we introduced a 
Tet-On myc-tagged PRL-3 construct into 293T cells. 48 hours after 
transfection, 293T cells were exposed to increasing concentrations of the 
tetracycline (Tc) derivative, doxycycline (Dox) for 24 hours to induce PRL-3 
expression. PRL-3 protein accumulated in a dose-dependent manner, and a 
corresponding increase in Leo1 protein levels was observed (Figure 3.3D). 
Thus, introduction of PRL-3 into 293T cells specifically up-regulates the 
expression of Leo1. To complement the overexpression studies, we also 
performed knockdown by transfecting PRL-3 siRNA into 293T cells. The 
degree of PRL-3 inhibition correlated to the dose of siRNA added, and Leo1 
was downregulated when 2.8 ug of siRNA was used (Figure 3.3E). 
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Collectively, these observations corroborated the MS results showing that 









Figure 3.3. Western blot validation of candidate proteins identified by 
MS. (A) Schematic overview of the reported downstream targets of PRL-3. 
(B) Expression of several representative up-regulated proteins, including 
Leo1, stathmin, HSP-90, hnRNPE1 and HDAC2 were compared between TF-
1 and TF1-hPRL3. (C) Knockdown of endogenous PRL-3 in AML cell lines 
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Molm-14 and HEL. The same panel of proteins was examined by western blot. 
(D) 293T cells were stably transfected with an inducible Tet-on myc-tagged 
PRL-3 construct, and increasing concentration of doxycyclin was used to 
induce PRL-3 expression for 48 hours. (E) 293T cells were transfected with 




3.4. Leo1 and PRL-3 levels are significantly associated in AML patient 
samples 
We examined PRL-3 mRNA levels in normal human peripheral blood, AML 
cell lines and primary patient AML cells, and found that PRL-3 and Leo1 are 
abnormally expressed at the mRNA level in AML cells (Figure 3.4A). Given 
that we observe a strong association between Leo1 and PRL-3 mRNA levels, 
we next determine whether Leo1 is similarly upregulated at the protein levels 
in AML patients. Western blot analysis of PRL-3 and Leo1 protein expression 
in an independent cohort of 24 primary AML samples found that 50% of the 
patient samples (Figure 3.4B) were positive for PRL-3 protein. This is in 
agreement with our previous findings that immunohistochemistry (IHC) 
staining for PRL-3 protein is positive in about 47% of patient bone marrow 
samples (Zhou J et al. 2011). Of these, only one did not express Leo1. 
Therefore, a strong association exists between PRL-3 and Leo1 expression 
(Chi-square p-value <0.01). On the other hand, Leo1 protein can be 
abundantly detected in 67% of the patient samples (Figure 3.4B). Leo1 is 
expressed in 5 samples with no PRL-3 expression, suggesting that other 
mechanisms may be responsible in these patient cases. Our findings 
demonstrated that a significant proportion of AML cases appeared to co-
express PRL-3 and Leo1, suggesting that Leo1 is a likely downstream target 
of PRL-3.  
 
To examine the clinical relevance of targeting PRL-3, we knockdown PRL-3 
in primary AML cells with high PRL-3 expression. We expanded three 
different AML patient cells in vitro, and examined the basal PRL-3 gene 
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expression. AML2 cells showed the highest expression of PRL-3 (Figure 
3.4C), and were used for transfection with either control or PRL-3 siRNA 
(Figure 3.4D). PRL-3 siRNA inhibited leukemic cell growth in a proliferation 
assay as compared to transfection with control siRNA (Figure 3.4E), 
suggesting that specific targeting of PRL-3 may have possible therapeutic 
applications in AML. 
 
In addition, we also performed a meta-analysis on a published dataset 
(Haferlach Leukemia dataset) to determine the differential gene expression of 
Leo1 in normal bone marrow versus AML cases. We detected higher Leo1 
levels in AML cases (Figure 3.4F).  
 
We also examined the basal expression levels of PRL-3 and Leo1 in normal 
human hematopoietic cell fractions, namely CD34+, T cell, B cell and myeloid 
cell. We collected peripheral blood from normal donor, and used CD3, CD33 
and CD20 antibodies to isolate the respective populations using flow 
cytometry. From the flow cytometry analysis, we can observed a clean 
separation of the three populations from a single sample (Figure 3.4G). 
Having sorted these cell populations, we found a relative correlation between 
PRL-3 and Leo1 mRNA levels. We observed that PRL-3 and Leo1 are 








































Figure 3.4. Leo1 and PRL-3 expression in human primary AML cells. (A) 
Gene expression of PRL-3 and Leo1 in AML cell lines and primary AML 
cells. β-actin was used as loading control. (B) Western blot was performed to 
show the expression levels of Leo1 and PRL-3 in an independent cohort of 24 
primary AML patient samples. β-actin was used as loading control. Chi-square 
test indicates highly significant association (P<0.01). (C) PRL-3 gene 
expression in human peripheral blood samples (PB) or acute myeloid leukemia 
samples (AML) from 3 independent sources. (D) Analysis of PRL-3 mRNA 
expression in AML2 cells transfected with either control siRNA or PRL-3 
siRNA. (E) Cell proliferation assay of primary AML cells transfected with 
either control siRNA or PRL-3 siRNA. (F) Meta-analysis of a published 
dataset for ethe xpression of Leo1 in normal donor vs AML cases. (G) Flow 
cytometry showing a clear separation of 3 cell populations based on CD 
antibodies staining (Q1 Dark purple: B cell; Q4 Yellow: T cell; Q3 Bright 
purple: granulocytes and monocytes). (H) Basal gene expression of PRL-3 and 
Leo1 in CD34, T cell, B cell and myeloid populations. **p<0.01 
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3.5. PRL-3 affects Leo1 mRNA levels through histone H3 lysine 9 
(H3K9me3) demethylation 
The mechanism of Leo1 regulation by PRL-3 could be at the transcriptional or 
translational levels. To examine how PRL-3 regulates Leo1, we perturbed 
PRL-3 mRNA with three shRNA constructs targeting different regions of 
PRL-3 to ensure specificity of inhibition. qRT-PCR demonstrated varied 
knockdown effects, with the most significant decrease seen with shRNA #780. 
For all PRL-3 shRNAs, efficient PRL-3 decrease was accompanied by a rapid 
and concomitant reduction of Leo1 transcripts levels, while there were no 
observable changes on PRL-3 and Leo1 levels upon transfection with a 
scrambled shRNA (Figure 3.5A). This suggests that PRL-3 regulates Leo1 at 
the mRNA level. 
 
Given that PRL-3 is not a DNA-binding protein, the transcriptional 
involvement of PRL-3 is likely to be indirect. A recent report implicated an 
epigenetic role of PRL-3 in colorectal cancer through regulating histone 
modifying enzymes involved in histone demethylation (Liu Y et al. 2013) To 
explore the possibility that PRL-3 upregulates Leo1 through histone 
methylation status in leukemic cells, we performed an unbasied screen of nine 
different permissive and repressive histone modifications in the TF-1 and TF1-
hPRL3 cells, and found the preferential alterations of histone methylation that 
were associated with a repressive state of chromatin. Specifically, an excess of 
PRL-3 leads to a global decrease in di- and tri-methylation at histone H3 
lysine 9 (H3K9me2 and 3) and histone H3 lysine 27 (H3K27me2 and 3) 
residues, whereas the levels of other tested epigenetic marks were mostly 
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unaffected (Figure 3.5B). Conversely, the global levels of H3K9me2, 
H3K9me3 and H3K27me3 were elevated in Molm-14 AML cells with stable 
PRL-3 knockdown (Figure 3.5C), confirming that PRL-3 expression affects 
these histone marks. 
 
To determine whether Leo1 activation is associated with local reductions in 
repressive histone methylation, we compared the basal levels of H3K9me2, 
H3K9me3 and H3K27me3 across Leo1 promoter region in the TF-1 and TF1-
hPRL3 cells. Chromatin immunoprecipitation (ChIP) experiments were 
performed with the respective antibodies, followed by qPCR amplification 
using four serial pairs of primers spanning Leo1 promoter region from -439 to 
-104 with respect to Leo1 transcriptional start site (TSS). In PRL-3 positive 
cells, a marked reduction in H3K9me3 occupancy was detected throughout the 
entire promoter region (P1-P4) as compared to the TF-1 cells, and H3K9me3 
seems to peak at P2 region (Figure 3.5D). Despite similar patterns observed 
with H3K9me2, it was not as pronounced as those seen with H3K9me3. Thus, 
Leo1 promoter appeared to be predominantly modulated by the levels of 
H3K9me3, which is a stronger repressive mark. In contrast, H3K27me3 levels 
were rare on the promoter, and thus minimal changes were observed with 
PRL-3 over-expression (Figure 3.5D). A control ChIP assay was performed 
using anti-H3 antibody and similar amounts of chromatin was 
immunoprecipitated in the TF-1 and TF1-hPRL3 cells (Figure 3.5D). 
Additional controls using rabbit IgG antibody showed minimal enrichment on 



















Figure 3.5. PRL-3 regulates Leo1 at the transcriptional level. (A) Molm-14 
cells were transfected with three different PRL-3 shRNA for 24 hours, and 
measured for Leo1 and PRL-3 mRNA levels. Error bars indicate ± SD; n=3. 
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(Right) Gel photo showing gene expression of PRL-3 and Leo1 in Molm-14 
cells with control or PRL-3 sh#780. (B) Nuclear extracts were obtained from 
TF-1 or TF1-hPRL3 cells, and immunoblot for respective histone marks. 
Histone H3 was used as the loading control. Intensity of bands was measured 
using ImageJ and provided as fold-increase using TF-1 as control. (C) Western 
blot analysis of H3K9me2, H3K9me3, H3 and H3K27me3 in Molm-14 cells 
transfected with either control or PRL-3 shRNAs. (D) Diagram of Leo1 
promoter showing the position of four different primer pairs (P1-P4) used for 
qPCR. ChIP was performed in TF-1 and TF1-hPRL3 cells with respective 
antibodies. Solid lines indicate ChIPs with the indicated antibodies, while 
dotted lines indicate control rabbit IgG; TF-1 cells are in black and TF1-




3.6. PRL-3 mediates H3K9me3 demethylation on Leo1 promoter through 
JMJD2C histone demethylase 
Having established that Leo1 promoter predominantly undergoes H3K9me3 
demethylation, we sought to identify which histone demethylase is involved in 
mediating this process. The search for enzymes capable of reversing 
trimethylation led to the identification of the JMJD2 family, including the 
JMJD2A, JMJD2B, JMJD2C and JMJD2D, to exhibit specific lysine-trimethyl 
demethylation activities (Figure 3.6A). To determine which JMJD2 member is 
important, we systematically knockdown the candidates and examine the 
impact on H3K9me3 levels and Leo1 expression. Due to the homology 
between the members of the JMJD2 family, we first checked the specificity of 
the shRNAs for their intended JMJD2 member. Together with positive 
selection using puromycin, the shRNAs were shown to efficiently achieve the 
knockdown effect, with little off-target effects observed on the other members 
of the JMJD2 family (Figure 3.6B). We observed that JMJD2C depletion in 
TF1-hPRL3 cells was able to increase the global levels of H3K9me3, 
accompanied by a reduction in Leo1 to similar levels as parental TF-1 cells 
(Figure 3.6C). While the levels of H3K9me3 mark also increased after 
JMJD2A, JMJB2B and JMJD2D knockdown, this did not translate to a 
reduction in Leo1 levels, implying the specific involvement of JMJD2C in 
regulating H3K9me3 related to Leo1 levels (Figure 3.6C). 
 
To directly demonstrate that JMJD2C regulates H3K9me3 on Leo1 promoter, 
we examine the occupancy of H3K9me3 and JMJD2C in TF1-hPRL3 cells 
after JMJD2C knockdown. We investigated the region P2 on Leo1 promoter, 
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which showed the greatest decrease in H3K9me3 levels after PRL-3 
overexpression (Figure 3.5D). Accordingly, knockdown of JMJD2C reduced 
the JMJD2C signal on Leo1 promoter and led to a 40% augmentation of the 
H3K9me3 signal (Figure 3.6D and 3.6E). Furthermore, H3K9me3 levels on 
Leo1 promoter were not regulated by JMJD2A, JMJD2B and JMJD2D, since 
shRNAs targeting these members did not significantly increase H3K9me3 on 
P2 (Figure 3.6F).  
 
Next, we examine how PRL-3 phosphatase regulates JMJD2C histone 
demethylase activity. There was no increase in JMJD2C protein expression in 
PRL-3 cells (Figure 3.6G), as well as no physical interaction between PRL-3 
and JMJD2C (Figure 3.6H). However, there is an increase in JMJD2C binding 
on Leo1 promoter in the TF1-hPRL3 as compared to TF-1 cells (Figure 3.6I). 
Thus, PRL-3 appears to recruit JMJD2C to Leo1 promoter through unknown 
mechanisms. An additional ChIP experiment was performed with anti-
JMJD2C antibody and extracts from our stable isogenic Molm-14 cell lines 
with PRL-3 or scrambled shRNAs to confirm the sole involvement of 
JMJD2C. JMJD2C association to the P2 region was significantly abrogated in 
the PRL-3 knockdown cells, supporting the notion that JMJD2C binds to the 
Leo1 promoter region dependent on the presence of PRL-3 protein (Figure 
3.6J). 
 
Taken together, these results demonstrated that PRL-3 relieves the repressive 
H3K9me3 mark on Leo1 promoter through JMJD2C, resulting in a 
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transcriptionally permissive chromatin state leading to the efficient promotion 







































Figure 3.6. JMJD2C regulates H3K9me3 on Leo1 promoter. (A) Diagram 
showing the functional domains JMJ-N, JMJ-C, PHD and TUDOR, in the 
JMJD2 proteins. (B) shRNAs specificity were tested in TF1-hPRL3 cells 
using JMJD2A, 2B, 2C and 2D primers. Graph is plotted relative to Mock. 
Error bars indicate ± SD, n=3. (C) TF1-hPRL3 transfected with Mock or 
JMJD2 shRNAs and analyzed by Western blot using the indicated antibodies. 
TF-1 was included for comparison. (D-E) ChIP was performed in TF1-hPRL3 
or TF1-hPRL3-JMJD2C shRNA using antibody against JMJD2C on P2 (D) or 
H3K9me3 (E). (F) H3K9me3 antibody was used for ChIP assay on promoter 
P2 region of TF1-hPRL3 and TF1-hPRL3 cells transfected with JMJD2A, 
JMJD2B or JMJD2D shRNA. Data shown as % Input. Data represent the 
mean ± SEM of triplicates. (G) Western blot of TF-1 and TF1-hPRL3 cell 
lysate with JMJD2C antibody. β-actin is used as loading control. (H) Lysate 
from TF1-hPRL3 cells were immunoprecipitated with either rabbit IgG, GFP 
(PRL-3) or JMJD2C antibody, and immunoblotted with the indicated 
antibodies. (I) ChIP was performed in TF-1 and TF1-hPRL3 cells using 
JMJD2C antibody on P1-P4. Data shown as % Input. Error bars indicate ± SD, 
n=3. (J) ChIP was performed in either Molm-14 or Molm14-PRL3 shRNA 
cells using antibody against JMJD2C across Leo1 promoter region P1-P4. 
Data shown as % Input. Data represent the mean ± SEM of triplicates. 
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3.7. Abrogation of Leo1 reduces PRL3-mediated oncogenesis 
To determine whether Leo1 contributes to PRL3-induced leukemic growth, we 
used lentiviral-based delivery of shRNAs to deplete Leo1 expression and 
looked at growth properties. Five different Leo1 shRNA clones targeting the 
coding region were evaluated for knockdown efficiency, and the most efficient 
sequence against Leo1 was used to abrogate Leo1 in the TF1-hPRL3 cells 
(Figure 3.7A). The cells were then subjected to puromycin selection for seven 
days before examination for differential cell growth capacities. To ensure the 
specificity of the system, non-targeting scrambled shRNA was used as the 
control. qRT-PCR analysis demonstrated a 5-fold reduction in Leo1 mRNA 
levels upon treatment with Leo1 #32 shRNA, and a marked reduction in the 
Leo1 protein levels (Figure 3.7B). On the contrary, no significant knockdown 
was observed with scrambled shRNA. We also included the TF-1 parental 
cells in the functional assays for comparison purposes. Notably, reduction in 
Leo1 levels significantly impaired growth of TF1-hPRL3 cells to growth rates 
comparable with TF-1 parental cells. (Figure 3.7C). No interferon response 
was induced at the concentration of virus used in all samples as measured by 
OAS-1 gene expression (Figure 3.7D).  
 
Stable overexpression of PRL-3 is sufficient to confer long-term cytokine-
independent growth of TF-1 cells. To determine whether loss of Leo1 affects 
the survival of TF1-hPRL3 without cytokine, we plated the cells in the 
absence of human IL-3 for 72 hours, followed by flow cytometric analysis for 
apoptotic markers annexin V-PE and 7-AAD. Although ~90% of TF1-hPRL3 
population was able to survive without supplementation of cytokine, Leo1 
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knockdown notably increases the factor withdrawal-induced apoptosis of TF1-
hPRL3 (Figure 3.7E), indicating that Leo1 abrogation removes the protective 
effect of PRL-3 towards cytokine deprivation.  
 
In vitro colony formation assays demonstrates that PRL-3 overexpression is 
sufficient to permit colony formation in methylcellulose cultures, indicating 
that PRL-3 enhances proliferation of leukemic cells in vitro. In contrast, Leo1 
knockdown in PRL-3 cells resulted in a significant reduction of the colony 
forming ability of TF1-hPRL3 cells, indicating a loss of clonogenic survival of 
these cells (Figure 3.7F). Leo1 knockdown also decreased the percentage of 
cells in S phase, indicating that it hindered the progression of cells into cell 
cycle (Figure 3.7G). These findings collectively indicated that Leo1 is an 
important mediator of cell growth and survival of the TF1-hPRL3 cells, and 









































Figure 3.7. Effects of stable Leo1 knockdown in TF1-hPRL3 cells. (A) 
Examination of the efficacy of the 5 different shRNA (sh#32-36) to 
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knockdown Leo1. (B) Knockdown of Leo1 in TF1-hPRL3 cells was analysed 
with qRT-PCR and western blot after stable selection for one week. β-actin 
was used as loading control. TF-1 was included for comparison. (C) Growth 
curve of TF-1, PRL3-scrambled and PRL3-Leo1 shRNA cells was determined 
by CellTitre-Glo luminescent assay. Cells were plated in 96-well format and 
grown for up to 4 days. Experiment was performed in triplicates. (D) 
Measurement of OAS-1 gene to exclude the possibility of interferon response 
activation in cells infected with virus. (E) TF-1, PRL3-scrambled and PRL3-
Leo1 shRNA were seeded in medium without human IL-3 for 48 h. The graph 
is plotted with the percentages of late apoptotic cells defined by Annexin V 
and 7-AAD positivity. (F) TF-1, PRL3-scrambled and PRL3-Leo1 shRNA 
cells were evenly suspended in HSC-CFU medium (StemMACS) and 
incubated for 10 days for colonies to develop before reading. (G) Cell cycle 
analysis of TF-1, PRL3-scrambled and PRL3-Leo1 shRNA cells. The 
percentage of cells in G1, S or G2/M were indicated. **p<0.01 
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3.8. Leo1 suppression depletes the levels of PAF complex components 
The PAF complex subunits have been shown to co-immunoprecipitate with 
each other in cells. Therefore, we checked whether knockdown of Leo1 affects 
the interaction network within the PAF complex. Interestingly, we found that 
loss of Leo1 destabilizes the PAF complex, and the mRNA levels of Paf1, 
Ctr9 and Ski8 were collectively downregulated (Figure 3.8A). In addition, we 
also examined the protein levels of Paf1 and Ctr9, and accordingly, the protein 
levels were also decreased with Leo1 depletion (Figure 3.8B).   
 
Since we established that PRL-3 is an upstream regulator of Leo1, and 
knockdown of PRL-3 downregulates Leo1, we further examine whether 
knockdown of PRL-3 similarly destabilizes the PAF complex. Interestingly, 
silencing PRL-3 downregulates all components of the PAF complex (Figure 
3.8C). Additionally, Cdc73 was also affected with PRL-3 knockdown (Figure 
3.8C), when it did not show a downregulation in the event of Leo1 knockdown 
(Figure 3.8A). To check the specificity of these downregulation effects seen 
with PRL-3 knockdown, we also knockdown PRL-3 in HL-60 cells which 
contain undetectable amounts of PRL-3 protein. Silencing of PRL-3 in HL-60 
cells did not have any effect on the PAF complex (Figure 3.8D). To confirm 
that destabilization of the PAF complex in PRL3-depleted cells is a result of 
loss of Leo1, we perform a rescue experiment by introducing Leo1 expression 
construct into PRL-3 knockdown cells. In both cases, restoration of Leo1 




















Figure 3.8. Leo1 knockdown destabilizes the PAF complex. (A-B) Molm-
14 cells were transfected with Leo1 shRNA (sh#32-36) for 48 h, and 
performed qRT-PCR (A) or western blot (B) analysis for the expression of the 
PAF complex components. (C) Molm-14 cells were transfected with PRL-3 
shRNA (sh#402, 404, 768, 774 and 780) for 48 h before analyzing the 
expression levels of the PAF complex components. (D) Analysis of PAF 
subunits after PRL-3 knockdown (sh#780) in PRL3-null HL-60 AML cells. 
(E) Molm-14 cells was co-transfected with PRL-3 shRNA (sh#780) and Leo1 
mock or expression construct for 48 h before qRT-PCR analysis of the 







3.9. Leo1 regulation of pluripotency genes as part of the PAF complex 
The PAF complex has been reported to be essential for embryonic stem cell 
identity and regulation of pluripotency genes. To determine the functional 
relevance of Leo1-mediated destabilization of PAF complex, we further 
examine the downstream effects of Leo1 knockdown on the several reported 
PAF complex-mediated pluripotency genes including OCT4, NANOG, SOX2, 
SOX4, TBX3, BMP4, TCL1 and KLF4. A subset of these genes, namely SOX2, 
SOX4 and TBX3 were significantly downregulated with Leo1 knockdown 
using 5 different shRNAs in Molm-14 cells (Figure 3.9A). Since PRL-3 is 
upstream of Leo1, and consistent with our aforementioned findings, 
knockdown of PRL-3 also led to similar effects on SOX2, SOX4 and TBX3 
(Figure 3.9A). 
 
Since knockdown of Leo1 destabilizes the PAF complex, it raises the question 
whether Leo1 plays an independent role in mediating oncogenic properties in 
AML. To determine whether Leo1 plays an independent role in mediating the 
oncogenic properties in AML or through PAF complex as a whole, we 
compared the effects of Leo1, Paf1 or Ctr9 knockdown in TF1-hPRL3 cells. 
We confirmed the knockdown efficiency using western blot (Figure 3.9B). 
Interestingly, we found that knockdown of Leo1 impeded cell proliferation to 
a greater extent than Paf1 or Ctr9 knockdown (Figure 3.9C). On the other 
hand, SOX2 and SOX4 expression levels were similarly affected in Leo1, Paf1 
or Ctr9 knockdown (Figure 3.9D). These observations suggested that although 
the entire PAF complex was partly involved in mediating oncogenesis though 
SOX genes, other mechanisms involving Leo1 alone may be present. 
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Furthermore, when we analyzed the expression levels of Leo1, Paf1, Cdc73, 




































Figure 3.9. Leo1 and PRL-3 knockdown downregulates pluripotency 
genes. (A) qRT-PCR analyses of pluripotency genes Sox2, Sox4 and Tbx3 
after Leo1 or PRL-3 knockdown in Molm-14 cells and normalized to the β-
actin. Graph is plotted relative to Mock. Error bars indicate ± SD. 1: Control 
siRNA, 2-6: shRNA #1 to #5. (B) Western blot analysis of Paf1, Ctr9 or Leo1 
after Paf1, Ctr9 or Leo1 siRNA transfection in TF1-hPRL3 cells. (C) After 
knockdown with the various siRNAs, the cells were used for cell proliferation 
assay up to 72 hours. (D) qRT-PCR analysis of Sox2, Sox4 and Tbx3 in Paf1, 
Ctr9 or Leo1 knockdown cells. (E) qRT-PCR of PAF complex components in 

























CHAPTER 4: PRL3-MEDIATED DEPHOSPHORYLATION OF LEO1 




4.1. PRL-3 is localized in the nucleus of AML cells 
In addition to an upregulation of Leo1 protein expression as revealed by the 
MS analysis, Leo1 also displayed a dephosphorylation status in the TF1-
hPRL3 cells as compared to TF1-EGFP cells. This suggested the possibility 
that Leo1 might be a direct substrate of PRL-3 phosphatase. We first examine 
the possibility of a direct interaction between PRL-3 and Leo1 by performing 
fractionation of the cellular compartments followed by immunoblotting of 
PRL-3 and Leo1. While Leo1 was expectedly found in the nucleus, 
endogenous and exogenous PRL-3 were distributed in both the nucleus and 
cytoplasm (Figure 4.1A). This suggested that in cells with high PRL-3 
expression, the oncogenic potential could be conferred by nuclear PRL-3 
through acquisition of novel nuclear functions. Immunofluorescence 
experiments also clearly showed the region of co-localization of PRL-3 and 
Leo1 in the nucleus, where majority of the cells displayed overlapping signals 
at the peri-nuclear region (Figure 4.1B). We further confirmed a similar 
localization pattern in two AML cell lines, Molm-14 and HEL (Figure 4.1C). 
These observations indicated that PRL-3 is present in both the nucleus and 
cytoplasmic fractions in AML cells. Given that PRL-3 and Leo1 co-exist in 










Figure 4.1. Leo1 and PRL-3 co-localize in the nucleus. (A) Nuclear and 
cytoplasmic extracts of TF-1 cells transfected with Emp-GFP or PRL3-GFP 
was used to determine the expression of endogenous and exogenous PRL-3 
and Leo1. Tubulin is the loading control for cytoplasmic extract (CE), and 
Lamin A is the loading control for nuclear extract (NE). (B) 
Immunoflorescence was performed on Molm-14 cells to show the 
colocalization of the PRL-3 and Leo1 signal. DAPI: Blue, PRL-3: Green, 
Leo1: Red, Merge: Yellow. (C) Endogenous PRL-3 and Leo1 expression in 
the NE, CE and whole cell lysate (WCL) of Molm-14 and HEL cells. 
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4.2. PRL-3 and Leo1 are regulated in a cell-cycle dependent manner 
Next, we examined the mechanisms regulating the localization of PRL-3 and 
Leo1. Leo1 and PRL-3 were respectively reported to be regulated in a cell-
cycle dependent manner. To determine whether there is a common point when 
PRL-3 and Leo1 accumulates in the cell-cycle, we synchronized the cells 
using a combination of double thymidine and nocodazole block to obtain 
enriched subpopulation of specific stages of the cell cycle (G1, S G2/M), and 
confirmed the profile using flow cytometry (Figure 4.2A and 4.2B). Molm-14 
cells were arrested at the G0/G1 boundary after double thymidine treatment 
(0"), and released into normal medium containing nocodazole. Cell-cycle 
progression was tracked at two hours (2"), three hours (3"), seven hours (7") 
and 24 hours (24") after release from double thymidine. Cell-cycle profile 
recorded by propidium iodide-mediated flow cytometry revealed that  77.8% 
of the cell population was in the G0/G1 phase just before release. The cells 
progressed into the cell-cycle in a synchronous manner, and entered S phase 
after two hours followed by G2/M phase after seven hours (Figure 4.2A and 
4.2B). We further confirm the cell-cycle profile through western blot of 
various cyclin molecules, which were known to be expressed in a cell cycle-
dependent manner. We can see an increase in Cyclin D1 at 0hrs, confirming 
that most cells were in the G1 phase. Cyclin A was upregulated at 3hrs, 
indicating S phase, and Cyclin B1 increasing at 7hrs indicated G2/M stage 
(Figure 4.2C). 
 
After we have a clear enrichment of different cell-cycle populations, each 
subpopulation was further examined for nuclear and cytoplasmic expression of 
124 
 
PRL-3 and Leo1. Notably, PRL-3 was located mainly in the cytoplasm in the 
G0/G1 phase, but accumulated in the nuclei at the S and G2/M phase. Both 












Figure 4.2. Leo1 and PRL-3 expression peaks at S phase in the cell-cycle. 
(A) Molm-14 cells were treated with double thymidine and then released into 
nocodazole-containing medium. Cells were collected at different time points 
and fixed in ice-cold 70% ethanol for FACS analysis. (B) Table showing a 
summary of the percentages of the cell population in different cell-cycle stages 
at the varying time points. (C) Cyclin D1, A and B1 were used to ascertain the 
cell-cycle stage of the segregated cell populations. (D) Cells at different cell-
cycle stages were lysed and used for detection of the expression levels of Leo1 
and PRL-3. Lamin A and tubulin were used to demonstrate the purity of the 
nuclear and cytoplasmic cell fractions, respectively. Western blot images were 
quantified using ImageJ and used to plot a graph to clearly show the trend of 




4.3. Substrate trapping mutants of PRL-3 confirmed interaction with 
Leo1 
Since PRL-3 and Leo1 co-localized in the nucleus, this strengthens the 
hypothesis that Leo1 may be a direct substrate of PRL-3. Identification of 
genuine substrates of a phosphatase is a challenge, due to the transient and 
promiscuous activity of the phosphatases. To circumvent this, we used 
substrate-trapping mutants of PRL-3 for in vivo co-immunoprecipitation 
assays to confirm whether Leo1 is a direct substrate of PRL-3. Basically, the 
substrate-trapping technique utilizes an attenuated phosphatase mutant to trap 
its cognate substrates such that it forms a stable complex for pull-downs. We 
created the C104S-GFP, D72A-GFP and D72A/C104S-GFP mutants of PRL-3 
with preserved structural integrity but possessed limited phosphatase activity. 
 
We first tested the ability of the mutants to ‘trap’ substrates at the global level. 
293T cells were transfected with the wild-type or PRL-3 mutants and 
immunoprecipitated with an anti-GFP antibody. The GFP immunoprecipitates 
were use to run SDS-PAGE. After probing with an anti-phosphoserine 
antibody of the whole membrane, we did not observe any serine 
phosphorylated proteins bound to the C104S, D72A or D72A/C104S mutants 
that were absent with the wild-type PRL3 (Figure 4.3A). This suggested that 
either the tested mutants do not function as substrate-trapping mutants, or the 
phospho-serine antibodies are not sensitive enough to identify changes at the 




Thus, we changed our strategy to focus on Leo1 alone. The C104S mutant has 
been previously shown to bind its substrates (e.g. Keratin-8 and Nucleolin) 
more strongly than wild-type PRL-3, suggesting that the C104S could function 
as a substrate-trapping mutant. We expressed the wild-type PRL-3 and C104S 
mutant in 293T cells and immunoprecipitated with an anti-GFP antibody. 
Rather than probing the entire membrane with anti-phosphoserine antibody, 
we probed with Leo1 to determine whether there is a stronger binding to the 
mutant PRL-3. Interestingly, Leo1 formed a stable complex with the C104S 
mutant, while this interaction was weaker in wild-type PRL-3 (Figure 4.3B), 






Figure 4.3. Identification of substrate-trapping mutants of PRL-3. (A) 
Wild-type and mutant GFP-tagged PRL-3 were expressed in 293T cells, 
followed by immunoprecipitation with an anti-GFP antibody. The entire 
precipitate was resolved using SDS-PAGE and stain with Commassie Blue to 
visualize all protein bands that were present. (B) GFP-tagged wild-type and 
C104S PRL-3 were expressed in 293T cells, followed by immunoprecipitation 
with an anti-GFP antibody. The precipitates were used to detect the presence 
of GFP and Leo1. 
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4.4. PRL-3 decreases Leo1 phospho-serine levels 
Next, we compared the total phospho-serine level of Leo1 between TF1-EGFP 
and TF1-hPRL3 cells. Since there are no commercial antibody to directly 
detect phospho-serine levels of Leo1 in whole cell lysate, we performed 
immunoprecipitation of Leo1 followed by probing with the phospho-serine 
antibody. Interestingly, we detected a significant reduction in total 
phosphoserine Leo1 levels (Figure 4.4A) in TF1-hPRL3 cells, suggesting that 
PRL-3 may dephosphorylate Leo1 on multiple serine residues. On the 
contrary, there was undetectable alteration in the levels of total phospho-
tyrosine and phospho-threonine. This was in agreement with the MS result 
where we identified changes primarily on the phospho-serine residues. 
 
To confirm that Leo1 is altered as a result of specific PRL-3 phosphatase 
activity, we expressed GFP-tagged wild-type and PRL-3 mutants, together 
with Flag-tagged Leo1 in 293T cells. Western blot analysis of GFP and Flag 
proteins confirmed the loading of the ectopic expression of the proteins at 
equal levels. We observed that C104S and D72A/C104S, which were known 
to completely abolish the phosphatase activity of PRL-3, led to a significant 
recovery of the phospho-serine Leo1 levels (Figure 4.4B). To prevent artifacts 
from the overexpression system, we also performed knockdown of PRL-3 in 
Molm-14 cells. As expected, knockdown of PRL-3 also affected Leo1 protein 
levels, therefore, the immunoprecipitation was performed using normalized 
amounts of Leo1 (Figure 4.4C). We demonstrated that knockdown of PRL-3 
in Molm-14 cells potently upregulates the phospho-serine Leo1 levels as 




There are two Leo1 serine phospho-antibodies that are commercially 
available, phospho-serine 10 (pS10) and phospho-serine 551 (pS551). To 
examine whether PRL-3 dephosphorylates Leo1 on these sites, we probed the 
whole cell lysate from TF-1 and TF1-PRL3. Both S10 and S551 residues 
showed a decrease in phosphorylation levels in TF1-hPRL3 as compared to 
TF-1 cells (Figure 4.4D). Given that we observed a significant reduction in the 
total phospho-serine levels of Leo1 in TF1-hPRL3 cells (Figure 4.4A), we 
believe that more serine sites are possibly modulated by PRL-3. To further 
demonstrate that the changes in S10 and S551 were a direct consequence of 
PRL-3 phosphatase activity, we transiently expressed GFP control, PRL3-GFP 
or C104S-GFP in TF-1 cells. Phosphorylation of S10 and S551 were 
downregulated in the presence of wild-type PRL-3, but not in catalytically-
inactive C104S mutant and empty vector control (Figure 4.4E), indicating that 












Figure 4.4. PRL-3 alters the phospho-serine levels of Leo1 through its 
phosphatase activity. (A) Leo1 protein was immunoprecipitated from TF1-
EGFP and TF1-hPRL3 cells respectively. The phosphoserine, phosphotyrosine 
and phosphothreonine status of Leo1 were compared between the isogenic cell 
lines. (B) Flag-tagged Leo1 and GFP-tagged PRL3 were co-expressed in 293T 
cells. The expression levels was confirmed by anti-Flag and anti-GFP 
antibodies. The phospho-serine status of Leo1 was compared among cells with 
wild-type or mutant PRL-3 overexpression. (C) Molm-14 cells were 
transfected with scrambled or PRL-3 shRNA, and equal amounts of 
immunoprecipitated Leo1 was used to compare the phospho-serine Leo1 
status. (D) Whole cell lysate (WCL) of TF-1 and TF1-hPRL3 cells were used 
to probe for total Leo1, phospho-S10 and phospho-S551. The protein levels 
are normalized to total Leo1 levels. (E) TF-1 cells were mock-transfected, or 
transfected with empty GFP vector, PRL3-GFP or C104S-GFP for 48 hours 
before harvesting for WCL, and probed with the indicated antibodies. The 






4.5. PRL-3 dephosphorylates Leo1 in an in vitro dephosphorylation assay 
To further ascertain that Leo1 is a direct substrate of PRL-3, we performed an 
in vitro dephosphorylation assay using purified PRL-3 protein and endogenous 
Leo1. We expressed GST-tagged human PRL-3 protein in E.coli cells. Since 
GST can be coupled to a glutathione matrix, it allows the use of an affinity 
column to purify protein in cells expressing the GST–fusion. In this case, we 
purified using a glutathione sepharose column. GST-tagged proteins were 
eluted under mild, non-denaturing conditions that will preserve protein 
function. Commassie blue staining demonstrated the purification of the protein 
eluate, as only a single band was observed (Figure 4.5A). As controls, we also 
included the GST protein and C104S-GST mutant.  
 
Since the mammalian protein was expressed in E.coli cells, we first 
determined whether the activity of the PRL-3 protein was preserved using the 
diFUMP PTPase assay. Measurement using the generic phosphatase substrate 
diFMUP demonstrated that significant phosphatase activity was contained in 
the PRL3-GST preparation but almost absent in the control GST and the 
attenuated C104S-GST extracts (Figure 4.5B). 
 
As shown in Figure 4.5C, anti-Leo1 antibody was used to immunoprecipitate 
endogenous Leo1, and equal amounts were used for the phosphatase assay. 
The serine phosphorylation level of the precipitated Leo1 was detected using 
an anti-phosphoserine antibody after the addition of GST, PRL3-GST or 
C104S-GST recombinant proteins. Increasing amounts of PRL-3 protein 
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significantly reduced the total Leo1 phospho-serine levels as compared to the 
addition of control GST. The addition of C104S-GST also showed some 
reduction in the phospho-serine levels, however, the increasing amounts of 
C104S-GST did not show a dose-dependent effect. Furthermore, the C104S 
mutant does not absolutely abolish the phosphatase activity of PRL-3, which 
could explain the “leakage” of phosphatase activity. Our date collectively 







Figure 4.5. In vitro phosphatase activity of PRL-3 on Leo1. (A) The 
presence and purification of the PRL-3 protein from the Glutathione sepharose 
column were assessed through Commassie Blue staining of the eluate. The 
bottom band is between 20-25kDa, while the top band is at 50kDa. Wild-type 
PRL-3 and C104S mutant have the same molecular size. (B) In vitro 
phosphatase assay was performed using diFMUP as a substrate to confirm the 
presence of phosphatase activity in the PRL3-GST eluted sample with respect 
to GST and C104S-GST. Phosphatase activity is expressed as the 
concentration of free phosphate released upon 1h and 2h incubation at 37°C. 
(C) Endogenous Leo1 protein was immunoprecipitated from 293T cells and 
added to 0.5 or 1µg of GST, PRL3-GST or C104S-GST containing buffer for 
in vitro phosphatase assay. 
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4.6. Leo1 forms a complex with β-catenin  
The β-catenin signaling pathway is aberrantly activated in many AML cases, 
and the upstream regulators mediating this pathway have not been completely 
identified. It was previously reported that endogenous Leo1 can be co-
immunoprecipitated with β-catenin through direct protein-protein interaction 
(Mosimann C et al. 2006). Therefore, we were interested to examine whether 
PRL-3 could activate the β-catenin signaling pathway through Leo1. 
 
To confirm the physical association between Leo1 and β-catenin, we 
performed immunoprecipitation with Leo1 antibody in 293T cells treated with 
litium chloride (LiCl). LiCl is a GSK-3β inhibitor, which prevents the 
degradation of β-catenin, thus promoting the accumulation of β-catenin. 
Western Blot demonstrated a 2-3-fold increase in the protein levels of β-
catenin after treatment with LiCl (Figure 4.6A). We found a clear association 
between Leo1 and β-catenin, suggesting that Leo1 can stably interact with β-
catenin in vivo (Figure 4.6A). We further performed the co-
immunoprecipitation experiment in the isogenic AML cells, TF-1 and TF1-
hPRL3. We did not treat the cells with LiCl to determine the endogenous 
interaction between β-catenin and Leo1. Since TF1-hPRL3 cells contain 
higher Leo1 levels, we normalized equal amounts of Leo1 protein 
immunoprecipitated in both cell lines for comparison. Interestingly, Leo1 
displayed a marked increase in the ability to form a complex with β-catenin in 









Figure 4.6. Leo1 interacts with β-catenin. (A) 293T cells were treated with 
40mM LiCl or NaCl for 16 hours before protein extraction. IP was performed 
using Leo1 antibody, and probed for β-catenin and Leo1. Input represents 5% 
of lysate used for IP. Rabbit IgG was used as IP control. (B) TF-1 or TF1-
hPRL3 cells were used for immunoprecipitation with rabbit IgG or Leo1 
antibodies. The IPs were immunoblotted with β-catenin and Leo1 antibodies.
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4.7. PRL-3 expression is associated with higher nuclear β-catenin 
β-catenin activates its downstream target genes through its ability to 
accumulate and translocate to the nucleus. In the nucleus, it interacts with 
components of the DNA-binding T cell factor/lymphoid enhancer factor 
(TCF/LEF) family proteins, acting as a transcriptional activator of its target 
genes. While the expression of total β-catenin is slightly elevated in the TF1-
hPRL3 cells (Figure 4.7A), we observed a more significant accumulation of 
nuclear β-catenin in the TF1-hPRL3 cells (Figure 4.7B). This was also 
accompanied by the detection of higher levels of activated β-catenin (non-
phosphorylation by GSK at sites Ser37 or Thr41) in the TF1-hPRL3 cells 
(Figure 4.7A).  
 
The ability to accumulate β-catenin in the nucleus was dependent on the 
phosphatase activity of PRL-3, since transfection of C104S-GFP reduced 
PRL3-induced accumulation of β-catenin in TF-1 cells (Figure 4.7C). 
Expression of PRL-3 in HL-60 cells also induced nuclear localization of β-
catenin (Figure 4.7D).  
 
Next, we determined the cause for a higher nuclear β-catenin in TF1-hPRL3 
cells. We performed fractionation of TF-1 and TF1-hPRL3 cells into nuclear 
and cytoplasmic lysate, and interestingly, we observed that almost all the β-
catenin is retained in the nucleus. This is in contrast to TF-1 cells, were β-
catenin is distributed between the nucleus and cytoplasm. Thus, PRL-3 was 
shown to enhance the nuclear localization of β-catenin, which is a prerequisite 











Figure 4.7. Higher nuclear β-catenin is associated with PRL-3. (A) 
Western blot showing the cellular levels of active β-catenin, total β-catenin 
and β-actin in TF-1 and TF1-hPRL3 cells. Anti-ABC antibody recognizes the 
functionally active form of β-catenin. (B) Nuclear β-catenin was detected 
using TF-1 and TF1-hPRL3 nuclear lysates after cellular fractionation. Lamin 
A is used as loading control. (C) TF-1 cells were mock-transfected, or 
transfected with GFP control, PRL3-GFP or C104S-GFP for 48 hours, and 
checked for nuclear presence of  β-catenin. (D) HL-60 cells were transfected 
with GFP control or PRL3-GFP for 48 hours, and checked for nuclear 
presence of  β-catenin. (E) TF-1 or TF1-hPRL3 cells were harvested for the 
nuclear and cytoplasmic fractions, and probed with β-catenin. Tubulin and 






4.8. PRL-3 activates the β-catenin signaling pathway 
To determine whether there is a downstream activation of β-catenin 
responsive genes subsequent to its nuclear accumulation, we performed the 
TOP-FLASH reporter assay. The TOP-FLASH reporter construct contains the 
wild-type TCF binding sites, which measures β-catenin binding and activation 
of gene transcription. The FOP-FLASH contains the mutated TCF sequences 
and acts as a negative control for the luciferase assay. We first determined 
whether the reporter plasmid is functional in 293T cells by incubating these 
cells with either NaCl (sodium chloride, negative control) or LiCl. The LiCl- 
treated cells cause a six-fold increase in the luciferase signal, indicating that 
the plasmid is responsive to β-catenin binding (Figure 4.8A).  
 
Next, we determine whether PRL-3 activates the β-catenin signaling pathway 
since it enhances nuclear localization of β-catenin. We transfected TF-1 and 
TF1-hPRL3 isogenic cell lines with the reporter construct, and found an 
endogenous two-fold increase in luciferase activity in the TF1-hPRL3 cells 
(Figure 4.8B). Since Leo1 directly interacts with β-catenin, we determined 
whether Leo1 overexpression is sufficient to activate the β-catenin signaling 
pathway. Interestingly, Leo1 protein increased β-catenin signaling by about 3-
fold (Figure 4.8C). This indicated that PRL3-mediated activation of β-catenin 




We also performed the TCF/LEF reporter assay in 293T cells transfected with 
pStar-PRL-3-myc inducible system, where PRL-3 protein expression can be 
induced by the addition of doxycycline (Figure 3.3D). Transcriptional 
activation of β-catenin was further shown to be correlated with PRL-3 
expression in a dose-dependent manner (Figure 4.8D). We also observed 
increased protein levels of the β-catenin responsive genes, cyclin D1 and c-
myc (Figure 4.8E). These data collectively points to a PRL3-mediated β-














Figure 4.8. PRL-3 activates β-catenin signaling. (A) 293T cells were 
transfected with TOP-FLASH or FOP-FLASH reporter construct for 24 hours, 
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followed by 40mM NaCl or LiCl treatment for a further 16 hours before 
performing luciferase assay. The luciferase activity was plotted as TOP-
FLASH/FOP-FLASH for this assay. (B) Transfection of TF-1 and TF1-hPRL3 
with TOP-FLASH or FOP-FLASH reporter construct for 24 hours before 
performing luciferase assay. The luciferase activity was plotted as TOP-
FLASH/FOP-FLASH for this assay. (C) TF-1 cells were transfected with 
either empty vector control or Leo1-Flag construct, together with TOP-
FLASH or FOP-FLASH constucts for 48 hours before performing the 
luciferase assay. (D) 293T cells were transfected with inducible PRL3-myc 
construct and TOP-FLASH or FOP-FLASH for 12 hours, followed by 
induction with varying doese of doxycycline for 12 hours before performing 
luciferase assay. (E) Western blot analysis of c-myc and cyclin D1 in TF-1 and 















5.1. Novel functions of PRL-3 in AML were revealed by functional 
phosphoproteomics 
Many human cancers arise due to the dysregulation of signal transduction 
networks within a cell. While the emergence of a high throughput technology 
like the microarray greatly advanced our understanding of downstream 
transcriptional changes in oncogenesis, critical events involved in cellular 
responses were mediated at the protein level and posttranslational 
modifications rather than transcriptional changes. Thus, development of a 
global and quantitative method for elucidating 
phosphorylation/dephosphorylation events would provide the missing link 
needed for an integrative view of PRL-3 activities in cancer. 
 
 We employed SILAC as the method to directly and accurately quantitate the 
differences between TF1-EGFP and TF1-hPRL3. To efficiently enrich for 
phosphopeptides, we performed ERLIC separation into multiple fractions to 
improve detection of lower abundance proteins. TF-1 cell line is chosen for 
manipulation since it contains low endogenous levels of PRL-3, and it is a 
cytokine-dependent cell line. When transformed, TF-1 acquires the ability to 
survive without cytokine supplementation, allowing us to study the effects of 
oncogenes in AML. 
 
Our present work represents the first large-scale quantitative survey of 
proteins regulated by PRL-3 in leukemia. At a false discovery rate (FDR) of 
1%, we quantified 803 proteins and 1163 unique phosphorylation sites. We 
identified several known proteins downstream of PRL-3 including Stathmin, 
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Nucleolin and Translationally Controlled Tumor Protein (TCTP) (Zheng P et 
al. 2010; Semba S et al. 2010; Chu ZH et al. 2011), which endorsed the 
validity of our approach. We also discovered additional candidate oncogenes 
that showed an upregulation, such as hnRNPH1, TPI1, HSP90B1, Prohibitin, 
as well as candidate tumor suppressors that were downregulated, such as 
POTE, nucleophosmin and BTF3, which were previously not known to be 
modulated by PRL-3 (Table S1). On the other hand, several reported 
substrates of PRL-3 in solid tumor cell lines, such as CDH22, Ezrin, Keratin8, 
Integrin-α1 and EF-2 were not identified in our screen, suggesting that PRL-3 
might activate both common and distinct networks in solid tumor carcinomas 
as compared to leukemia. 
 
From our comprehensive proteomic dataset, we gained several novel insights 
into the functions of PRL-3. First, we found that PRL-3 unexpectedly altered 
the expression levels of a significant number of nuclear proteins (50%), 
although it was reported to localize predominantly in the plasma membrane 
and cytosol due to the CAAX membrane-targeting signal (Zeng Q et al. 2003). 
Despite this, there has been an escalating number of articles that observed a 
nuclear localization of PRL-3. Using GFP-tagged wild-type PRL-3 and C104S 
mutant for immunoprecipitation, one group (Semba S et al. 2010) found a 
physiological interaction between PRL-3 and Nucleolin. Since Nucleolin is 
known to be a major nucleolar phosphoprotein, the authors also examined the 
localization of PRL-3 through fractionation in SW480 colorectal cells, and 
they observed the presence of PRL-3 in the nucleus. In a separate article, 
examination of PRL-3 localization in various stages of CRC clinical samples 
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revealed the accumulation of nuclear PRL-3 in the advanced stages of CRC 
(Liu Y et al. 2012). Furthermore, PRL-3 was also found to shuttle between the 
nucleus and cytoplasm in myeloma and AML cells (Fagerli et al. 2008, Al- 
Aidaroos et al. 2010). These data lend support to our hypothesis that PRL-3 
may acquire novel functions in the nucleus that is responsible for 
leukemogenesis. 
 
Second, gene ontology annotation by biological process revealed a specific 
involvement of PRL-3 in pre-mRNA splicing (5.7%), nucleic acid metabolism 
(19.7%), cell-cycle regulation (7.1%) and cell motility (6.0%). Involvement in 
cell motility was consistent with published reports that over-expression of 
PRL-3 in solid tumor carcinomas have been linked to processes such as 
enhanced cell migration, invasion and metastasis (Zeng Q et al. 2003; 
Fiordalisi JJ et al. 2006). On the other hand, this is the first study to suggest 
that PRL-3 plays a role in the regulation of RNA-related processes.  
 
Third, PRL-3 is a class I cysteine-based PTP, and categorized into the 
subfamily of VH1-like vaccina virus gene H1 dual-specificity phosphatases 
(the DSP family). This subclass comprises of members that possess serine-, 
threonine- and tyrosine-specific phosphatase activities (Alonso A et al. 2004; 
Julien SG et al. 2011). Our MS result also demonstrated that PRL3-induced 
phosphorylation events occurred on serine, threonine and tyrosine residues, 
with 80% of differential phosphorylation observed on serine residues (Figure 
3.2D). The specific enrichment of serine residues that were modulated by 
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PRL-3 is in agreement with other reports that PRL-3 affected the phospho-
serine residues of its cellular substrates (e.g. Ezrin and Keratin 8) (Forte E et 
al. 2008; Mizuuchi E et al. 2009).  
 
Overall, our unbiased approach enabled us to implicate novel candidate 
proteins in the oncogenic function of PRL-3, which would fundamentally 
advance our understanding of how this phosphatase contributes to cancer 
progression.    
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5.2. PRL-3 hijacked the histone demethylation network to aberrantly 
activate its target gene, Leo1 
There were few reports on how PRL-3 regulates its targets, partly due to the 
challenges in identifying the genuine targets of PRL-3. In our present study, 
we identified and validated Leo1 as one of the most important targets of PRL-
3. Western blot analyses of PRL-3 overexpression and knock-down systems in 
multiple AML cell lines demonstrated a clear positive association between 
PRL-3 and Leo1 protein levels (Figure 3.3). More importantly, this association 
was also significant in a cohort of AML patient samples that we examined 
(Figure 3.4B). We further found that the association between PRL-3 and Leo1 
was observed not only at the protein levels, but also correlated well at the 
mRNA levels. This suggests that PRL-3 might be regulating Leo1 at the 
transcript level. Although it is conceivable that PRL-3 potentially regulates 
Leo1 through other transcription factors, we were more interested to examine 
the novel role of PRL-3 as an epigenetic regulator in light of a recent 
publication. Liu Y et al. found two members of the Jumonji domain-
containing protein family, JMJD1B and JMJD2B, as PRL-3 associated 
proteins using proteomic methods (Zheng P et al. 2010; Liu Y et al. 2013).  
 
Our results suggested that H3K9me3 is the predominant histone mark 
involved in PRL-3 overexpression, while H3K9me2 and H3K27me3 played a 
minor role (Figure 3.5B and 3.5D). Trimethylation of H3K9 is a strong 
repressive epigenetic mark generally associated with heterochromatin 
maintenance and transcriptional repression, and deregulation of H3K9me3 
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levels has been shown to cause aberrant gene expression, contributing to the 
development of various human cancers (Cloos et al. 2006; Bannister et al. 
2011). Furthermore, we observed a global demethylation of H3K9 in PRL-3 
overexpressing cells, indicating that alterations in a histone demethylase led to 
these widespread epigenetic changes (Fullgrabe et al. 2011).  
 
H3K9me3 has been long regarded as a ‘permanent’ epigenetic mark, and the 
existence of enzymes capable of reversing lysine trimethylation have been 
initially questioned. When investigators began searching for protein 
complexes that can interact with H3K9me3, JMJD2C was identified. JMJD2C, 
originally identified as GASC1, is a gene located on chromosome 9p, a region 
frequently amplified in cancers (Cloos et al. 2006). JMJD2C belongs to the 
JMJD2 subfamily of the Jumonji family, which consists of four main 
members, JMJD2A, JMJD2B, JMJD2C and JMJD2D, and two other 
pseudogenes, JMJD2E and JMJD2F. JMJD2A, JMJD2B and JMJD2C share a 
common domain architecture that consist of one JMJN and JMJC (catalytic 
motif), and two PHD and TUDOR domains (Katoh M et al. 2004). A 
phylogenic analysis of these genes showed that it is evolutionarily conserved 
from C.elegans to humans. The members of this subfamily have been clearly 
demonstrated to demethylate H3K9me3/me2 to various extends in vitro using 
MALDI-TOF mass spectrometry, and in vivo (Whetstine JR et al. 2006).  
 
Since all four members of the JMJD2 subfamily possess the ability to 
demethylate H3K9me3, we used an unbiased approach to identify which 
enzyme(s) was involved. We observed that downregulation of JMJD2C was 
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the only enzyme capable of reversing Leo1 levels in TF1-hPRL3 cells at the 
protein level (Figure 3.6C), and this was dependent on the occupancy and 
direct demethylase activity of JMJD2C through the reversal of H3K9me3 
mark on Leo1 promoter (Figure 3.6D, 3.6E and 3.6I). The involvement of 
other JMJD2 members was minimal (Figure 3.6C and 3.6F).  
 
It is then of interest to clarify the precise mechanism of how PRL-3, a 
phosphatase, regulates the activities of JMJD2C, a histone demethylase. Liu Y 
et al. previously investigated the relationship between PRL-3 and 
JMJD1B/JMJD2B, and found that PRL-3 regulates the protein levels of 
JMJD1B and JMJD2B. However, this observation was not supported in our 
case, as we did not observe any increase in JMJD2C protein levels in TF1-
hPRL3 cells (Figure 3.6G). We further checked for physical interaction 
between PRL-3 and JMJD2C, which was negative as well (Figure 3.6H). 
Thus, how PRL-3 affects the binding of JMJD2C or possibly other histone 
demethylase on the promoters of target genes remains to be determined.  
 
Although it may be unorthodox for PRL-3 to regulate its targets through a 
transcriptional mechanism rather than through its phosphatase activity, our 
observation is consistent with a study by Al-aidaroos et al., where they found 
a synergistic effect between PRL-3 and EGFR. Hyperactivation of EGFR 
activity was attributed to the transcriptional downregulation of protein tyrosine 
phosphatase 1B (PTP1B), an inhibitory phosphatase for EGFR. Although the 
authors did not address the mechanism of PTP1B downregulation by PRL-3, 
they mentioned the possibility of epigenetic modifications of the PTP1B locus 
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(Al-aidaroos et al. 2013). With this observation, we propose that regulation 
through histone demethylation is not restricted to Leo1, but can be extended to 
other PRL-3 targets. 
 
Although we cannot discount the involvement of other histone marks and 
histone-modifying enzymes that were unexamined in our experiments, the 
regulation of H3K9me3 and its corresponding histone demethylase, JMJD2C, 
on Leo1 promoter by PRL-3, is unquestionable. Thus, PRL-3 may induce 
epigenetic instability through JMJD2C as an early event to promote further 
genetic alterations and activation of multiple downstream target genes. 
Importantly, our results demonstrated a possible interface between the 




5.3. Leo1 and the PAF complex were implicated in PRL3-mediated 
leukemogenesis 
Among the validated upregulated proteins modulated by PRL-3 was Leo1, 
component of the PAF complex. The PAF complex, composed of five core 
subunits, Paf1, Leo1, Cdc73, Ski8 and Ctr9, have been implicated in crucial 
biologic processes such as RNA processing, transcription initiation and 
elongation, and transcript start site selection (Stolinski LA et al. 1997; Costa 
PJ et al. 2000; Penheiter KL et al. 2005). While the PAF complex has been 
frequently found to co-localize with RNA polymerase II on chromatin to 
regulate promoters and coding regions of actively transcribed genes, loss of 
PAF complex subunits do not alter the abundance nor the distribution of RNA 
polymerase II on transcribed genes (Mueller CL et al. 2004). This suggested 
that the PAF complex has distinct functions independent of RNA polymerase 
II.  
 
Through its ability to directly recruit to chromatin and regulate gene 
transcription, PAF complex has been reported to play an essential role in 
embryonic development, survival, and maintenance of ESC identity 
(Mosimann C et al. 2006; Wang P et al. 2008; Ding L et al. 2009). The PAF 
complex, in particular Cdc73, was found to mediate the transcriptional outputs 
of the Wnt/β-catenin signaling pathway on its target genes (Mosimann C et al. 
2006). Analysis of conventional and conditional Cdc73 knockout mice 
demonstrated embryonic lethality or death, and identification of genes 
regulated by the PAF complex revealed those involved in essential cell growth 
and survival pathways (Wang P et al. 2008). In a primary screen for Oct4 
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modulators in maintaining stem cell identity, PAF complex was identified and 
shown to bind to the promoters of key pluripotency genes to mediate a 
H3K4me3 mark, representing actively transcribed genes. More importantly, 
overexpression of PAF is sufficient to block differentiation of ESCs (Ding L et 
al. 2009). Of particular interest to us, the PAF complex has been shown to 
promote leukemogenesis through interaction with MLL, a H3K4 histone 
methyltransferase. Rearrangements involving MLL is one of the most 
common genetic alterations in leukemia, affecting about 5% of all AML cases. 
Similarly, recruitment of the PAF complex to MLL target loci stimulates 
transcription, especially in the upregulation of HOX genes that is crucial for 
MLL-mediated transformation. Furthermore, two differentiation leukemic 
models demonstrated a downregulation of PAF complex expression upon 
myeloid differentiation of leukemic cells, while forced expression of PAF 
complex inhibits myeloid differentiation (Muntean AG et al. 2010). 
Collectively, these findings suggested that PAF complex played a pivotal role 
in maintaining pluripotency in progenitor cells. 
 
Further emphasizing the importance of PAF complex in diverse cellular 
processes, recent studies have characterized individual PAF complex subunits 
as candidate tumor suppressors or oncogenes in a tumor-specific context 
(Chaudhary K et al. 2007). The proteins that make up the PAF complex vary 
in their domain structures and exhibit different cellular localizations, 
expanding the myriad of activities that PAF complex is potentially involved 
in. Paf1, the founding member of the complex, is located on a recurrent 
amplicon in pancreatic adenocarcinoma, and overexpression is associated with 
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enhanced growth advantage and tumorigenesis (Moniaux N et al. 2006). 
Intriguingly, another well-studied subunit of the complex, Cdc73, is a putative 
tumor suppressor gene with inactivating mutations in hyperthyroidism-jaw 
tumor familial cancer syndrome, sporadic parathyroid cancer and isolated 
cases of familial hyperthyroidism. Overexpression of Cdc73 potently inhibited 
cell proliferation through repression of expression of cyclin D1 (Woodard GE 
et al. 2005). The ambiguity of Cdc73 in cancer is exemplified in another paper 
showing the adaptation of a pro- or anti-oncogenic identity based on the 
tyrosine phosphorylation status of Cdc73 (Takahashi A et al. 2011). Here, our 
data established Leo1 as a proto-oncogene in AML. PRL-3 is a potent 
oncogene in solid tumors and leukemia, and the expression levels of Leo1 is 
positively associated with PRL-3 in both cell lines and AML patient samples 
(Figure 3.4A and 3.4B). Furthermore, depletion of Leo1 affected the 
proliferation, growth and survival of AML cells, with a milder effect on cell-
cycle (Figure 3.7). An oncogenic phosphatase regulating the PAF complex is 
not without precedence. SHP2, an oncogenic protein tyrosine phosphatase, 
associates with the entire PAF complex. The investigators demonstrated that 
Cdc73 is a phospho-tyrosine substrate of SHP2, and the dephosphorylated 
form of Cdc73 can aberrantly activate Wnt signaling through stable interaction 
with β-catenin (Takahashi A et al. 2011).  
 
To better understand the independence and interplay among the subunits of the 
PAF complex, it is important to define the interaction network within the PAF 
complex. Deletion and co-expression reconstitution studies of the subunits had 
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been performed in insect cells. Paf1 appeared to be the key scaffold protein, 
and Paf1 and Cdc73 were the two subunits directly interacting with Leo1 (Kim 
JH et al. 2010). To better understand the role of Leo1 in the structural 
organization of PAF complex, we assessed the effects of Leo1 silencing on the 
expression levels of other PAF components. We discovered that the levels of 
Paf1, Ski8, Ctr9 were significantly affected by the loss of Leo1 (Figure 3.8A 
and 3.8B). Our observation thus supports the notion of an inter-dependency 
within the PAF complex as reported by other investigators. However, the 
levels of Cdc73 were not in concert to the expression changes of the other 
subunits, suggesting that the regulation on Cdc73 is more complicated. Future 
studies would shed light on the mechanisms regulating the expression levels of 
these subunits, and how this would affect the functionality of the PAF 
complex. Depletion of PRL-3 similarly downregulated the components of the 
PAF complex, which can be rescued by the expression of Leo1 (Figure 3.8C 
and 3.8E). This again clearly demonstrated that PRL-3 is the upstream 
regulator of Leo1.   
 
Since depletion of Leo1 affected the levels of Ski8, Ctr9 and Paf1, it raised an 
important question as to whether Leo1 played an independent role in 
mediating the oncogenic properties in AML. To address this, we performed 
single knockdowns of Leo1, Paf1 or Ctr9 in TF1-hPRL3 cells, and found that 
loss of Leo1 was the most significant in reversing the oncogenic effects of 
PRL-3 (Figure 3.9C). Furthermore, our gene expression analysis of the PAF 
complex components revealed that solely Leo1 was upregulated in TF1-
hPRL3 cells (Figure 3.9E). This suggested that while the entire PAF complex 
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played a minor role, Leo1 alone has important functions independent of the 
PAF complex.  This led us to our second hypothesis, that Leo1 is a direct 
substrate of PRL-3. This is supported by our mass spectrometry data where 
Leo1 is one of the 192 phosphoproteins that was differentially regulated in 
TF1-hPRL3 cells.  
 
Several key pluripotency genes, such as OCT4, NANOG, SOX2, SOX4, TBX3, 
BMP4, TCL1 and KLF4, were reported to be regulated by the PAF complex 
(Ding L et al. 2009). To investigate the underlying mechanism by which PRL-
3 and Leo1/PAF complex work to promote oncogenesis, we analyzed this set 
of genes in PRL-3 or Leo1 knockdown cells.  A subset of these genes, namely 
SOX2, SOX4 and TBX3 were significantly downregulated upon PRL-3 or Leo1 
depletion (Figure 3.9A). Interestingly, Leo1, Paf1 or Ctr9 single knockdown 
also resulted in the downregulation of SOX2, SOX4 and TBX3 (Figure 3.9D), 
suggesting that the regulation of pluripotency genes is coordinated by the PAF 
complex as a whole, and that loss of any subunits would affect the ability of 
the complex to regulate these genes.  
 
An independent bioinformatics study was performed in our laboratory to 
identify genes that are associated with PRL-3. Interestingly, in transcription 
profiles of patient samples with high PRL-3 expression, members of the SOX 
family emerged as being upregulated. Furthermore, the deregulation of SOX 
genes, especially SOX4, is an important collaborating driver of myeloid 
leukemogenesis in several transgenic murine models of leukemia (Sandoval S 
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et al. 2012). Thus, our study suggested that PRL-3 could exert oncogenic 
properties in AML through Leo1 and PAF complex-mediated deregulation of 
critical pluripotency genes that were previously implicated in leukemogenesis.  
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5.4. PRL-3 dephosphorylates Leo1 at serine residues in the nucleus 
In addition to Leo1 protein changes in PRL-3 overexpressing cells, we 
detected two unique Leo1 phosphopeptides with a decrease in serine 
phosphorylation. This prompted us to investigate whether Leo1 is a direct 
substrate of PRL-3. Earlier, we discussed that varying reports have observed a 
nuclear or cytoplasmic localization of PRL-3 in cancer cells. Since Leo1 is a 
nuclear protein, we were particularly interested to determine whether PRL-3 
and Leo1 could co-localize in the nucleus. We performed fractionation and 
found that while Leo1 was exclusively found in the nucleus, PRL-3 was 
evenly distributed between the two compartments. Immunofluorescence 
experiments further pinpoint that PRL-3 and Leo1 both resided in the peri-
nuclear region in leukemic cells (Figure 4.1A and 4.1B). In light of this, there 
are two possible explanations for a nuclear PRL-3: (1) an absence of 
prenylation or (2) simple diffusion.  
 
Since PRL-3 was found in both compartments, we were interested to 
determine the mechanism that regulates the basal distribution of PRL-3 in 
leukemic cells. Through literature mining, we noted that PRL-3 and Leo1 
were separately mentioned to be regulated by cell-cycle. By isolating cells in 
various cell-cycle stages and analyzing the expression levels of PRL-3 and 
Leo1 in the nucleus, we found an oscillatory pattern where both expression 
peaks at S phase. These observations collectively provided evidence on the 




It was not surprising to find PRL-3 activity in the nucleus. A report showed 
that nasant PRL members are primarily oxidized inside cells (Skinner AL et 
al. 2009). Oxidation occurred at the conserved C104 residue, rendered the 
PRL proteins unable to bind to their substrates and inhibited the catalytic 
activity of PRL. However, oxidation is reversible in vitro and in vivo. The 
oxidation depends on the presence of reactive oxidants, and the redox 
environment of the cells. Thus, the subcellular localization of PRLs may play 
a role in the regulation of the phosphatase activity, and localization is 
influenced by factors such as tissue type, cell cycle stage and prenylation 
status. With respect to the redox conditions, the nucleus is the most reducing 
organelle in the cell, and hence is the ideal environment for PRL-3 activity.  
 
Due to the transient nature of a phosphatase-substrate interaction, it has been 
difficult to isolate substrates using wild-type PRL-3. Thus, development of 
substrate-trapping mutants was used to isolate phosphatase substrates in vivo. 
For example, mutagenesis study on the invariant residues on PTP1B led to the 
discovery of D181A that converts the enzyme into a ‘substrate-trap’, and the 
subsequent identification of EGF receptor as its physiological substrate (Flint 
AJ et al. 1997). Further development of this technique led to the discovery of 
the D181A/Q262A mutant which possessed a higher substrate-binding 
affinity, allowing the identification of novel, less abundant substrates that were 
missed by D181A (Xie L et al. 2002). In the case of PRL-3 phosphatase, 
keratin-8 and nucleolin were previously identified using the C104S mutant of 
PRL-3 in colorectal carcinoma (Mizuuchi E et al. 2009; Semba S et al. 2010). 
The C104S mutant replaces the active site cysteine with a serine residue, and 
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this single amino acid change abolishes the phosphatase activity of PRL-3, but 
preserves all structural integrity of the enzyme. When we introduced the wild-
type and C104S PRL-3 to immunoprecipitate Leo1, we detected stronger 
binding of Leo1 with C104S PRL-3, indicating that these two proteins interact 
in vivo (Figure 4.3B).  
 
Leo1 contains 66 serine, 7 threonine and 4 tyrosine phosphosites as predicted 
by NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/). Since PRL-3 is a 
dual-specificity phosphatase, we determined whether PRL-3 displays a 
preferential dephosphorylation towards one or more types of modifications on 
Leo1. We found that PRL-3 overexpression decreased the phosphorylation 
level on serine residues to a significant extend (Figure 4.4A). This suggested 
that PRL-3 might dephosphorylate Leo1 at multiple serine sites. Next, we 
demonstrated that the serine dephosphorylation activity observed on Leo1 was 
due to the specific phosphatase activity of PRL-3, since ‘phosphatase-dead’ 
mutants were able to reverse the dephosphorylation effect (Figure 4.4B). More 
importantly, we were able to demonstrate direct phosphatase-substrate 
relationship of PRL-3 and Leo1 in the in vitro dephosphorylation assay 
(Figure 4.5C). Using Leo1 phospho-specific antibodies, we identified S10 and 
S551 as phosphosites that were inversely correlated with PRL-3 
overexpression (Figure 4.4D and 4.4E). This confirms that PRL-3 activity 




5.5. PRL-3 regulates β-catenin activity in leukemic cells through Leo1 
The Wnt/β-catenin signaling pathway is frequently dysregulated in solid tumor 
cancers. Mutations occurring in Axin, APC or β-catenin resulted in the 
accumulation of nuclear β-catenin and transcriptional activation of specific 
target genes involved in oncogenesis (Morin PJ, 1999). There have been 
mounting evidence that β-catenin has analogous oncogenic functions in 
leukemia. Upregulation of β-catenin occurs in a large proportion of AML 
patient samples, associated with increased clonogenicity of blast cells, and is a 
novel independent prognostic factor predicting poor outcome and survival 
(Chung EJ et al, 2002; Ysebaert L et al, 2006).  
 
While it was established that β-catenin is involved in the pathogenesis of 
AML, the mechanistic basis for the dysregulation of β-catenin in AML is 
unclear. Screening for β-catenin mutations in multiple leukemic cell lines 
(HL-60, K-562, Jurkat, Molt-4) showed the absence of mutations. Therefore, 
it was suggested that accumulation of nuclear β-catenin, rather than mutations, 
play a more significant cause in leukemia. It is also interesting to note that β-
catenin mRNA and protein levels were not strictly correlated, indicating that 
β-catenin is most likely regulated through translational or post-translational 
mechanisms in AML cells (Ysebaert L et al, 2006). 
 
In our present study, we have demonstrated a strong casual link between PRL-
3 and Leo1. Since Leo1 has been reported to form a complex with β-catenin in 
the nucleus (Mosimann C et al, 2006), this prompted us to investigate the 
existence of a PRL-3→Leo1→β-catenin signaling axis in AML. We checked 
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for the expression of total β-catenin, activated β-catenin and nuclear β-catenin 
in TF-1 and TF1-hPRL3 cells (Figure 4.7A and 4.7B), and detected a 
significant expression of β-catenin in the nucleus of TF1-hPRL3 cells. To 
determine the cause of a higher nuclear β-catenin, we fractionated TF-1 and 
TF1-hPRL3 cells, and observed a significant retention of β-catenin in the 
nucleus, while β-catenin in TF-1 cells were distributed between the nucleus 
and cytoplasm. We combined this with the fact that we observed a 
dephosphorylation of Leo1 in the TF1-hPRL3 cells. These multiple lines of 
evidence led us to propose a hypothesis whereby dephosphorylated Leo1, a 
direct consequence of PRL-3 phosphatase activity, facilitated stronger binding 
to β-catenin, and retained β-catenin in the nucleus. An alternative hypothesis 
is that the dephosphorylation of Leo1 led to the stability of Leo1 protein, 
which facilitated the binding with β-catenin. However, when similar amounts 
of Leo1 were used to immunoprecipitate β-catenin, a stable complex was 
formed solely in the TF1-hPRL3 cells (Figure 4.6B).  
 
Our hypothesis is supported by another publication showing that the 
phosphorylation status of Cdc73, another component of the PAF complex, 
influenced β-catenin interaction. Through combinational site-directed 
mutagenesis of 11 evolutionally-conserved tyrosine residues on Cdc73, they 
identified Y290/293/315 as the phosphosites which displayed elevated binding 
affinity towards β-catenin (Takahashi A et al, 2011).  
 
Both Flt3 abnormalities and chromosomal translocations have been associated 
with aberrant Wnt/β-catenin signaling in AML (Mikesch JH et al, 2007). For 
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instance, the fusion products of AML-ETO1, PML-RARɑ and PLZF-RARɑ 
induced the expression of plakoglobin, which is a co-activator of TCF and 
LEF transcription factors, and is also able to directly compete with β-catenin 
for binding to the APC/axin destruction complex (Müller-Tidow C et al, 
2004). On the other hand, microarray analysis of genes induced by Flt3-ITD 
revealed an upregulation of Frizzled-4, one of Wnt receptors (Tickenbrock L 
et al, 2005). However, certain AML patients neither harbour Flt3 
abnormalities nor chromosomal translocations, but demonstrated aberrant 
Wnt/β-catenin signaling.  
 
We have reasons to believe that PRL-3 is a novel upstream regulator of β-
catenin. There was a recent report on the regulation of β-catenin by IL-3 
signaling. In response to IL-3, TF-1 and AML patient leukemic cells displayed 
increased β-catenin protein levels, nuclear localization of β-catenin and 
transcriptional induction of β-catenin target genes (Sadras T  et al, 2014). 
Interestingly, stable transfection with PRL-3 in TF-1 cells was sufficient to 
transform these cells from IL-3 dependency to IL-3 independency (Figure 
1.19), suggesting that PRL-3 activates downstream pathways that overlap with 
the IL-3 signaling pathway. In addition, PRL-3 is overexpressed in Flt3-ITD 
positive AML (n=78) as compared to Flt3-ITD negative AML cells (n=206) 
(Zhou J et al, 2011). The activation of PRL-3 in Flt3-ITD may be the possible 




PRL-3 was first reported as a metastasis stage-specific gene in CRC, whereas 
Wnt signaling is activated at the initial stages of CRC. This seems to suggest 
that Wnt activation should precede PRL-3 overexpression. However, in AML, 
PRL-3 overexpression has been associated with properties like cell growth 
and colony-forming ability rather than metastasis, and do not demonstrate a 
stage-specific activation. Moreover, the ability of PRL-3 to activate β-catenin 
is through its direct interaction with Leo1 in the nucleus, and PRL-3 is found 
to be present in the cytoplasm of CRC cells. We thus conclude that the 
mechanisms that activate Wnt/β-catenin signaling differ in solid carcinomas 
and leukemias.  
 
Given that the Wnt/β-catenin signaling is important in several leukemogenic 
pathways, novel treatment strategies exploiting the targeted modulation of this 
pathway in AML will be beneficial. Moreover, blocking the Wnt/β-catenin 
signaling pathway has been demonstrated to inhibit tumor growth and induces 
apoptosis of cancer cells (Verma UN et al, 2003; Huang SM et al, 2009). 
Here, we propose the targeting of β-catenin in AML cells expressing high 
PRL-3. Despite the promising results from the inhibition of PRL-3 in in vitro 
and in vivo studies, no anti-PRL3 agents have reached clinical trials. Thus, 





5.6. Future prospects 
PRL-3 has been reported to be regulated through various mechanisms in solid 
tumour and leukemic cell lines. Therefore, it will be interesting to examine the 
underlying mechanisms of PRL-3 overexpression in AML, especially primary 
patient samples. It will also be biologically significant to demonstrate that 
PRL-3 expression can transform myeloid cells. 
 
In this study, we detected significant serine dephosphorylation of Leo1 by 
PRL-3 phosphatase. The immediate pending experiment would be to map all 
the Leo1 phosphosites that were modulated by PRL-3 through targeted mass 
spectrometry. Our initial large-scale phosphoproteomic study,which aim to 
identify all phosphorylation changes at the global level, did not provide 
sufficient information on Leo1 as an individual protein. Furthermore, 
systematic site-directed mutagenesis of potential phosphosites is not a viable 
option here, since Leo1 is a 110kDa protein with 66 potential serine 
phosphosites, and in most cases, multiple sites need to be mutated to 
sufficiently detect a change in phosphorylation level and modulation of 
downstream activity. Subsequent to the identification of the exact 
phosphosites, Leo1 phospho-specific antibodies need to be developed to 
confirm that PRL-3 can dephosphorylate Leo1 at that particular site in vivo. 
 
Our data showed that PRL-3 overexpression is associated with higher levels of 
total and nuclear β-catenin in multiple AML cell lines. It would therefore be 
important to demonstrate a similar correlation in expression patterns in AML 
patient samples. A tissue microarray of a cohort of AML samples followed by 
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immunohistochemistry staining of PRL-3 and β-catenin would provide useful 
data of the statistical relationship of these proteins. If such a relationship is 
proven to be true, PRL-3 overexpression can be a predictive biomarker for 
favorable response towards small molecule inhibitors targeting β-catenin, 

























CHAPTER 6: CONCLUSION AND PROPOSED MODEL 
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To draw a comprehensive picture of PRL-3 function in AML, we review our 
current results to assemble into a cohesive model of PRL3-mediated 
oncogenic signaling (Figure 6.1). Usually, in the course of cancer 
development, more than one cellular pathway is disrupted, and this was indeed 
observed in cells with the acquisition of PRL-3 expression. Our work 
demonstrated the cooperation between PRL-3 and Leo1/PAF complex, and 
showed that two major pathways, Sox and β-catenin, were aberrantly activated 
leading to the oncogenic phenotypes observed in PRL-3 overexpressing cells.  
 
In the PAF-dependent pathway, PRL-3 enhances the occupancy of JMJD2C 
on Leo1 promoter, thereby removing the repressive histone marks H3K9me3 
and H3K9me2, to promote the expression of Leo1. Leo1 and the PAF complex 
were then recruited to promoters of pluripotency genes including the SOX 
genes to activate their transcription (Figure 6.1A). In the PAF-independent 
pathway, PRL-3 directly associates with Leo1 in the nucleus, and 
dephosphorylates Leo1 on multiple serine residues. Leo1 then formed a stable 
complex with β-catenin that retains it in the nucleus, conferring the 
constitutive activation of β-catenin target gene expression (Figure 6.1B).  
 
In conclusion, with the identification of 398 proteins and 192 phosphoproteins 
that were differentially regulated as a result of PRL-3 overexpression, our 
work allowed the identification of bona fide PRL-3 targets, which established 
starting points for a complete enumeration of PRL-3 function in AML 
signaling. Taken together, this study provided novel insights into the 
mechanisms by which PRL-3 promotes the malignant phenotype in AML, 
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which strongly suggest that PRL3-induced oncogenic network should become 






Figure 6.1. Model of PRL-3 mediated oncogenesis through Leo1. (A) PAF-
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